Compounds and methods for immunotherapy and diagnosis of tuberculosis

ABSTRACT

Compounds and methods for inducing protective immunity against  tuberculosis  are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more  M. tuberculosis  proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against  M. tuberculosis  infection, or may be used for the diagnosis of  tuberculosis.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Ser. No.9/025,197, filed Feb. 18, 1998; which is a continuation-in-part of U.S.application Ser. No. 08/942,578, filed Oct. 1, 1997; which is acontinuation-in-part of U.S. application Ser. No. 08/818,112, filed Mar.13, 1997; which is a continuation-in-part of U.S. application Ser. No.08/730,510, filed Oct. 11, 1996; which claims priority from PCTApplication No. PCT/US 96/14674, filed Aug. 30, 1996; and is acontinuation-in-part of U.S. application Ser. No. 08/680,574, filed Jul.12, 1996; which is a continuation-in-part of U.S. application Ser. No.08/659,683, filed Jun. 5, 1996; which is a continuation-in-part of U.S.application Ser. No. 08/620,874, filed Mar. 22, 1996, now abandoned;which is a continuation-in-part of U.S. application Ser. No. 08/533,634,filed Sep. 22, 1995, now abandoned; which is a continuation-in-part ofU.S. application Ser. No. 08/523,436, filed Sep. 1, 1995, now abandoned.

TECHNICAL FIELD

The present invention relates generally to detecting, treating andpreventing Mycobacterium tuberculosis infection. The invention is moreparticularly related to polypeptides comprising a Mycobacteriumtuberculosis antigen, or a portion or other variant thereof, and the useof such polypeptides for diagnosing and vaccinating againstMycobacterium tuberculosis infection.

BACKGROUND OF THE INVENTION

Tuberculosis is a chronic, infectious disease, that is generally causedby infection with Mycobacterium tuberculosis. It is a major disease indeveloping countries, as well as an increasing problem in developedareas of the world, with about 8 million new cases and 3 million deathseach year. Although the infection may be asymptomatic for a considerableperiod of time, the disease is most commonly manifested as an acuteinflammation of the lungs, resulting in fever and a nonproductive cough.If left untreated, serious complications and death typically result.

Although tuberculosis can generally be controlled using extendedantibiotic therapy, such treatment is not sufficient to prevent thespread of the disease. Infected individuals may be asymptomatic, butcontagious, for some time. In addition, although compliance with thetreatment regimen is critical, patient behavior is difficult to monitor.Some patients do not complete the course of treatment, which can lead toineffective treatment and the development of drug resistance.

Inhibiting the spread of tuberculosis requires effective vaccination andaccurate, early diagnosis of the disease. Currently, vaccination withlive bacteria is the most efficient method for inducing protectiveimmunity. The most common Mycobacterium employed for this purpose isBacillus Calmette-Guerin (BCG), an avirulent strain of Mycobacteriumbovis. However, the safety and efficacy of BCG is a source ofcontroversy and some countries, such as the United States, do notvaccinate the general public. Diagnosis is commonly achieved using askin test, which involves intradermal exposure to tuberculin PPD(protein-purified derivative). Antigen-specific T cell responses resultin measurable induration at the injection site by 48-72 hours afterinjection, which indicates exposure to Mycobacterial antigens.Sensitivity and specificity have, however, been a problem with thistest, and individuals vaccinated with BCG cannot be distinguished frominfected individuals.

While macrophages have been shown to act as the principal effectors ofM. tuberculosis immunity, T cells are the predominant inducers of suchimmunity. The essential role of T cells in protection against M.tuberculosis infection is illustrated by the frequent occurrence of M.tuberculosis in AIDS patients, due to the depletion of CD4 T cellsassociated with human immunodeficiency virus (HIV) infection.Mycobacterium-reactive CD4 T cells have been shown to be potentproducers of gamma-interferon (IFN-γ), which, in turn, has been shown totrigger the anti-mycobacterial effects of macrophages in mice. While therole of IFN-γ in humans is less clear, studies have shown that1.25-dihydroxy-vitamin D3, either alone or in combination with IFN-γ ortumor necrosis factor-alpha, activates human macrophages to inhibit M.tuberculosis infection. Furthermore, it is known that IFN-γ stimulateshuman macrophages to make 1.25-dihydroxy-vitamin D3. Similarly, IL-12has been shown to play a role in stimulating resistance to M.tuberculosis infection. For a review of the immunology of M.tuberculosis infection see Chan and Kaufmann in Tuberculosis:Pathogenesis, Protection and Control, Bloom (ed.), ASM Press,Washington, D.C., 1994.

Accordingly, there is a need in the art for improved vaccines andmethods for preventing, treating and detecting tuberculosis. The presentinvention fulfills these needs and further provides other relatedadvantages.

SUMMARY OF THE INVENTION

Briefly stated, this invention provides compounds and methods forpreventing and diagnosing tuberculosis In one aspect, polypeptides areprovided comprising an immunogenic portion of a soluble M. tuberculosisantigen, or a variant of such an antigen that differs only inconservative substitutions and/or modifications. In one embodiment ofthis aspect, the soluble antigen has one of the following N-terminalsequences:

(a) (SEQ ID No. 120) Asp-Pro-Val-Asp-Ala-Val-Ile-Asn-Thr-Thr-Cys-Asn-Tyr-Gly-Gln-Val-Val-Ala-Ala-Leu; (b) (SEQ ID No. 121)Ala-Val-Glu-Ser-Gly-Met-Leu-Ala-Leu-Gly-Thr-Pro- Ala-Pro-Ser; (c) (SEQID No. 122) Ala-Ala-Met-Lys-Pro-Arg-Thr-Gly-Asp-Gly-Pro-Leu-Glu-Ala-Ala-Lys-Glu-Gly-Arg; (d) (SEQ ID No. 123)Tyr-Tyr-Trp-Cys-Pro-Gly-Gln-Pro-Phe-Asp-Pro-Ala- Trp-Gly-Pro; (e) (SEQID No. 124) Asp-Ile-Gly-Ser-Glu-Ser-Thr-Glu-Asp-Gln-Gln-Xaa- Ala-Val;(f) (SEQ ID No. 125) Ala-Glu-Glu-Ser-Ile-Ser-Thr-Xaa-Glu-Xaa-Ile-Val-Pro; (g) (SEQ ID No. 126)Asp-Pro-Glu-Pro-Ala-Pro-Pro-Val-Pro-Thr-Thr-Ala- Ala-Ser-Pro-Pro-Ser;(h) (SEQ ID No. 127) Ala-Pro-Lys-Thr-Tyr-Xaa-Glu-Glu-Leu-Lys-Gly-Thr-Asp-Thr-Gly; (i) (SEQ ID No. 128)Asp-Pro-Ala-Ser-Ala-Pro-Asp-Val-Pro-Thr-Ala-Ala-Gln-Leu-Thr-Ser-Leu-Leu-Asn-Ser-Leu-Ala-Asp-Pro-Asn-Val-Ser-Phe-Ala-Asn; (j) (SEQ ID No. 134)Xaa-Asp-Ser-Glu-Lys-Ser-Ala-Thr-Ile-Lys-Val-Thr- Asp-Ala-Ser; (k) (SEQID No. 135) Ala-Gly-Asp-Thr-Xaa-Ile-Tyr-Ile-Val-Gly-Asn-Leu-Thr-Ala-Asp; or (l) (SEQ ID No. 136)Ala-Pro-Glu-Ser-Gly-Ala-Gly-Leu-Gly-Gly-Thr-Val- Gln-Ala-Gly;wherein Xaa may be any amino acid.

In a related aspect, polypeptides are provided comprising an immunogenicportion of an M. tuberculosis antigen, or a variant of such an antigenthat differs only in conservative substitutions and/or modifications,the antigen having one of the following N-terminal sequences:

(m) (SEQ ID No. 137) Xaa-Tyr-Ile-Ala-Tyr-Xaa-Thr-Thr-Ala-Gly-Ile-Val-Pro-Gly-Lys-Ile-Asn-Val-His-Leu-Val; or (n) (SEQ ID No. 129)Asp-Pro-Pro-Asp-Pro-His-Gln-Xaa-Asp-Met-Thr-Lys-Gly-Tyr-Tyr-Pro-Gly-Gly-Arg-Arg-Xaa-Phe;wherein Xaa may be any amino acid.

In another embodiment, the soluble M. tuberculosis antigen comprises anamino acid sequence encoded by a DNA sequence selected from the groupconsisting of the sequences recited in SEQ ID Nos.: 1, 2, 4-10, 13-25,52, 99 and 101, the complements of said sequences, and DNA sequencesthat hybridize to a sequence recited in SEQ ID Nos.: 1, 2, 4-10, 13-25,52, 99 and 101 or a complement thereof under moderately stringentconditions.

In a related aspect, the polypeptides comprise an immunogenic portion ofa M. tuberculosis antigen, or a variant of such an antigen that differsonly in conservative substitutions and/or modifications, wherein theantigen comprises an amino acid sequence encoded by a DNA sequenceselected from the group consisting of the sequences recited in SEQ IDNos.: 26-51, 138, 139, 163-183, 201, 240, 242-247, 253-256, 295-298,309, 316, 318-320, 322, 324, 328, 339, 333, 335, 337, 339 and 341, thecomplements of said sequences, and DNA sequences that hybridize to asequence recited in SEQ ID Nos.: 26-51, 138, 139, 163-183, 201, 240,242-247, 253-256, 295-298, 309, 316, 318-320, 322, 324, 328, 329, 333,335, 337, 339 and 341 or a complement thereof under moderately stringentconditions.

In related aspects, DNA sequences encoding the above polypeptides,expression vectors comprising these DNA sequences and host cellstransformed or transfected with such expression vectors are alsoprovided.

In another aspect, the present invention provides fusion proteinscomprising a first and a second inventive polypeptide or, alternatively,an inventive polypeptide and a known M. tuberculosis antigen.

Within other aspects, the present invention provides pharmaceuticalcompositions that comprise one or more of the above polypeptides, or aDNA molecule encoding such polypeptides, and a physiologicallyacceptable carrier. The invention also provides vaccines comprising oneor more of the polypeptides as described above and a non-specific immuneresponse enhancer, together with vaccines comprising one or more DNAsequences encoding such polypeptides and a non-specific immune responseenhancer.

In yet another aspect, methods are provided for inducing protectiveimmunity in a patient, comprising administering to a patient aneffective amount of one or more of the above polypeptides.

In further aspects of this invention, methods and diagnostic kits areprovided for detecting tuberculosis in a patient. The methods comprisecontacting dermal cells of a patient with one or more of the abovepolypeptides and detecting an immune response on the patient's skin. Thediagnostic kits comprise one or more of the above polypeptides incombination with an apparatus sufficient to contact the polypeptide withthe dermal cells of a patient.

In yet other aspects, methods are provided for detecting tuberculosis ina patient, such methods comprising contacting dermal cells of a patientwith one or more polypeptides encoded by a DNA sequence selected fromthe group consisting of SEQ ID Nos.: 3, 11, 12, 140, 141, 156-160,189-193, 199, 200, 203, 215-225, 237, 239, 261-276, 292, 293, 303-308,310-315, 317, 321, 323, 325-327, 330-332, 334, 336, 338, 340 and342-347, the complements of said sequences, and DNA sequences thathybridize to a sequence recited in SEQ ID Nos.: 3, 11, 12, 140, 141,156-160, 189-193, 199, 200, 203, 215-225, 237, 239, 261-276, 292, 293,303-308, 310-315, 317, 321, 323, 325-327, 330-332, 334, 336, 338, 340and 342-347; and detecting an immune response on the patient's skin.Diagnostic kits for use in such methods are also provided.

These and other aspects of the present invention will become apparentupon reference to the following detailed description and attacheddrawings. All references disclosed herein are hereby incorporated byreference in their entirety as if each was incorporated individually.

BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE IDENTIFIERS

FIGS. 1A and B illustrate the stimulation of proliferation andinterferon-γ production in T cells derived from a first and a second M.tuberculosis-immune donor, respectively, by the 14 Kd, 20 Kd and 26 Kdantigens described in Example 1.

FIG. 2 illustrates the stimulation of proliferation and interferon-γproduction in T cells derived from an M. tuberculosis-immune individualby the two representative polypeptides TbRa3 and TbRa9.

FIGS. 3A-D illustrate the reactivity of antisera raised againstsecretory M. tuberculosis proteins, the known M. tuberculosis antigen85b and the inventive antigens Tb38-1 and TbH-9, respectively, with M.tuberculosis lysate (lane 2), M. tuberculosis secretory proteins (lane3), recombinant Tb38-1 (lane 4), recombinant TbH-9 (lane 5) andrecombinant 85b (lane 5).

FIG. 4A illustrates the stimulation of proliferation in a TbH-9-specificT cell clone by secretory M. tuberculosis proteins, recombinant TbH-9and a control antigen, TbRa11.

FIG. 4B illustrates the stimulation of interferon-y production in aTbH-9-specific T cell clone by secretory M. tuberculosis proteins, PPDand recombinant TbH-9.

FIGS. 5A and B illustrate the stimulation of proliferation andinterferon-γ production in TbH9-specific T cells by the fusion proteinTbH9-Tb38-1.

FIGS. 6A and B illustrate the stimulation of proliferation andinterferon-γ production in Tb38-1-specific T cells by the fusion proteinTbH9-Tb38-1.

FIGS. 7A and B illustrate the stimulation of proliferation andinterferon-γ production in T cells previously shown to respond to bothTbH-9 and Tb38-1 by the fusion protein TbH9-Tb38-1.

FIGS. 8A and B illustrate the stimulation of proliferation andinterferon-γ production in T cells derived from a first M.tuberculosis-immune individual by the representative polypeptides XP-1,RDIF6, RDIF8, RDIF10 and RDIF11.

FIGS. 9A and B illustrate the stimulation of proliferation andinterferon-γ production in T cells derived from a second M.tuberculosis-immune individual by the representative polypeptides XP-1,RDIF6, RDIF8, RDIF10 and RDIF11.

SEQ. ID NO.1 is the DNA sequence of TbRa1.

SEQ. ID NO.2 is the DNA sequence of TbRa10.

SEQ. ID NO.3 is the DNA sequence of TbRa11.

SEQ. ID NO.4 is the DNA sequence of TbRa12.

SEQ. ID NO.5 is the DNA sequence of TbRa13.

SEQ. ID NO.6 is the DNA sequence of TbRa16.

SEQ. ID NO.7 is the DNA sequence of TbRa17.

SEQ. ID NO.8 is the DNA sequence of TbRa18.

SEQ. ID NO.9 is the DNA sequence of TbRa19.

SEQ. ID NO.10 is the DNA sequence of TbRa24.

SEQ. ID NO.11 is the DNA sequence of TbRa26.

SEQ. ID NO.12 is the DNA sequence of TbRa28.

SEQ. ID NO.13 is the DNA sequence of TbRa29.

SEQ. ID NO.14 is the DNA sequence of TbRa2A.

SEQ. ID NO.15 is the DNA sequence of TbRa3.

SEQ. ID NO.16 is the DNA sequence of TbRa32.

SEQ. ID NO.17 is the DNA sequence of TbRa35.

SEQ. ID NO.18 is the DNA sequence of TbRa36.

SEQ. ID NO.19 is the DNA sequence of TbRa4.

SEQ. ID NO.20 is the DNA sequence of TbRa9.

SEQ. ID NO.21 is the DNA sequence of TbRaB.

SEQ. ID NO.22 is the DNA sequence of TbRaC.

SEQ. ID NO.23 is the DNA sequence of TbRaD

SEQ. ID NO.24 is the DNA sequence of YYWCPG.

SEQ. ID NO.25 is the DNA sequence of AAMK.

SEQ. ID NO.26 is the DNA sequence of TbL-23.

SEQ. ID NO.27 is the DNA sequence of TbL-24.

SEQ. ID NO.28 is the DNA sequence of TbL-25.

SEQ. ID NO.29 is the DNA sequence of TbL-28.

SEQ. ID NO.30 is the DNA sequence of TbL-29.

SEQ. ID NO.31 is the DNA sequence of TbH-5.

SEQ. ID NO.32 is the DNA sequence of TbH-8.

SEQ. ID NO.33 is the DNA sequence of TbH-9.

SEQ. ID NO.34 is the DNA sequence of TbM-3.

SEQ. ID NO.35 is the DNA sequence of TbM-3.

SEQ. ID NO.36 is the DNA sequence of TbM-1.

SEQ. ID NO.37 is the DNA sequence of TbM-7.

SEQ. ID NO.38 is the DNA sequence of TbM-9.

SEQ. ID NO.39 is the DNA sequence of TbM-12.

SEQ. ID NO.40 is the DNA sequence of TbM-13.

SEQ. ID NO.41 is the DNA sequence of TbM-14.

SEQ. ID NO.42 is the DNA sequence of TbM-15.

SEQ. ID NO.43 is the DNA sequence of TbH4.

SEQ. ID NO.44 is the DNA sequence of TbH-4-FWD.

SEQ. ID NO.45 is the DNA sequence of TbH-12.

SEQ. ID NO.46 is the DNA sequence of Tb38-1.

SEQ. ID NO.47 is the DNA sequence of Tb38-4.

SEQ. ID NO.48 is the DNA sequence of TbL-17.

SEQ. ID NO.49 is the DNA sequence of TbL-20.

SEQ. ID NO.50 is the DNA sequence of TbL-21.

SEQ. ID NO.51 is the DNA sequence of TbH-16.

SEQ. ID NO.52 is the DNA sequence of DPEP.

SEQ. ID NO.53 is the deduced amino acid sequence of DPEP.

SEQ. ID NO.54 is the protein sequence of DPV N-terminal Antigen.

SEQ. ID NO.55 is the protein sequence of AVGS N-terminal Antigen.

SEQ. ID NO.56 is the protein sequence of AAMK N-terminal Antigen.

SEQ. ID NO.57 is the protein sequence of YYWC N-terminal Antigen.

SEQ. ID NO.58 is the protein sequence of DIGS N-terminal Antigen.

SEQ. ID NO.59 is the protein sequence of AEES N-terminal Antigen.

SEQ. ID NO.60 is the protein sequence of DPEP N-terminal Antigen.

SEQ. ID NO.61 is the protein sequence of APKT N-terminal Antigen.

SEQ. ID NO.62 is the protein sequence of DPAS N-terminal Antigen.

SEQ. ID NO.63 is the deduced amino acid sequence of TbRa1.

SEQ. ID NO.64 is the deduced amino acid sequence of TbRa10.

SEQ. ID NO.65 is the deduced amino acid sequence of TbRa11.

SEQ. ID NO.66 is the deduced amino acid sequence of TbRa12.

SEQ. ID NO.67 is the deduced amino acid sequence of TbRa13.

SEQ. ID NO.68 is the deduced amino acid sequence of TbRa16.

SEQ. ID NO.69 is the deduced amino acid sequence of TbRa17.

SEQ. ID NO.70 is the deduced amino acid sequence of TbRa18.

SEQ. ID NO.71 is the deduced amino acid sequence of TbRa19.

SEQ. ID NO.72 is the deduced amino acid sequence of TbRa24.

SEQ. ID NO.73 is the deduced amino acid sequence of TbRa26.

SEQ. ID NO.74 is the deduced amino acid sequence of TbRa28.

SEQ. ID NO.75 is the deduced amino acid sequence of TbRa29.

SEQ. ID NO.76 is the deduced amino acid sequence of TbRa2A.

SEQ. ID NO.77 is the deduced amino acid sequence of TbRa3.

SEQ. ID NO.78 is the deduced amino acid sequence of TbRa32.

SEQ. ID NO.79 is the deduced amino acid sequence of TbRa35.

SEQ. ID NO.80 is the deduced amino acid sequence of TbRa36.

SEQ. ID NO.81 is the deduced amino acid sequence of TbRa4.

SEQ. ID NO.82 is the deduced amino acid sequence of TbRa9.

SEQ. ID NO.83 is the deduced amino acid sequence of TbRaB.

SEQ. ID NO.84 is the deduced amino acid sequence of TbRaC.

SEQ. ID NO.85 is the deduced amino acid sequence of TbRaD.

SEQ. ID NO.86 is the deduced amino acid sequence of YYWCPG.

SEQ. ID NO.87 is the deduced amino acid sequence of TbAAMK.

SEQ. ID NO.88 is the deduced amino acid sequence of Tb38-1.

SEQ. ID NO.89 is the deduced amino acid sequence of TbH-4.

SEQ. ID NO.90 is the deduced amino acid sequence of TbH-8.

SEQ. ID NO.91 is the deduced amino acid sequence of TbH-9.

SEQ. ID NO.92 is the deduced amino acid sequence of TbH-12.

SEQ. ID NO.93 is the amino acid sequence of Tb38-1 Peptide 1.

SEQ. ID NO.94 is the amino acid sequence of Tb38-1 Peptide 2.

SEQ. ID NO.95 is the amino acid sequence of Tb38-1 Peptide 3.

SEQ. ID NO.96 is the amino acid sequence of Tb38-1 Peptide 4.

SEQ. ID NO.97 is the amino acid sequence of Tb38-1 Peptide 5.

SEQ. ID NO.98 is the amino acid sequence of Tb38-1 Peptide 6.

SEQ. ID NO.99 is the DNA sequence of DPAS.

SEQ. ID NO.100 is the deduced amino acid sequence of DPAS.

SEQ. ID NO.101 is the DNA sequence of DPV.

SEQ. ID NO.102 is the deduced amino acid sequence of DPV.

SEQ. ID NO.103 is the DNA sequence of ESAT-6.

SEQ. ID NO.104 is the deduced amino acid sequence of ESAT-6.

SEQ. ID NO.105 is the DNA sequence of TbH-8-2.

SEQ. ID NO.106 is the DNA sequence of TbH-9FL.

SEQ. ID NO.107 is the deduced amino acid sequence of TbH-9FL.

SEQ. ID NO.108 is the DNA sequence of TbH-9-1.

SEQ. ID NO.109 is the deduced amino acid sequence of TbH-9-1.

SEQ. ID NO.110 is the DNA sequence of TbH-9-4.

SEQ. ID NO.111 is the deduced amino acid sequence of TbH-9-4.

SEQ. ID NO.112 is the DNA sequence of Tb38-1F2 IN.

SEQ. ID NO.113 is the DNA sequence of Tb38-2F2 RP.

SEQ. ID NO.114 is the deduced amino acid sequence of Tb37-FL.

SEQ. ID NO.115 is the deduced amino acid sequence of Tb38-IN.

SEQ. ID NO.116 is the DNA sequence of Tb38-1F3.

SEQ. ID NO.117 is the deduced amino acid sequence of Tb38-1F3.

SEQ. ID NO.118 is the DNA sequence of Tb38-1F5.

SEQ. ID NO.119 is the DNA sequence of Tb38-1F6.

SEQ. ID NO.120 is the deduced N-terminal amino acid sequence of DPV.

SEQ. ID NO.121 is the deduced N-terminal amino acid sequence of AVGS.

SEQ. ID NO.122 is the deduced N-terminal amino acid sequence of AAMK.

SEQ. ID NO.123 is the deduced N-terminal amino acid sequence of YYWC.

SEQ. ID NO.124 is the deduced N-terminal amino acid sequence of DIGS.

SEQ. ID NO.125 is the deduced N-terminal amino acid sequence of AEES.

SEQ. ID NO.126 is the deduced N-terminal amino acid sequence of DPEP.

SEQ. ID NO.127 is the deduced N-terminal amino acid sequence of APKT.

SEQ. ID NO.128 is the deduced amino acid sequence of DPAS.

SEQ. ID NO.129 is the protein sequence of DPPD N-terminal Antigen.

SEQ ID NO. 130-133 are the protein sequences of four DPPD cyanogenbromide fragments.

SEQ ID NO.134 is the N-terminal protein sequence of XDS antigen.

SEQ ID NO.135 is the N-terminal protein sequence of AGD antigen.

SEQ ID NO.136 is the N-terminal protein sequence of APE antigen.

SEQ ID NO.137 is the N-terminal protein sequence of XYI antigen.

SEQ ID NO.138 is the DNA sequence of TbH-29.

SEQ ID NO.139 is the DNA sequence of TbH-30.

SEQ ID NO.140 is the DNA sequence of TbH-32.

SEQ ID NO.141 is the DNA sequence of TbH-33.

SEQ ID NO.142 is the predicted amino acid sequence of TbH-29.

SEQ ID NO.143 is the predicted amino acid sequence of TbH-30.

SEQ ID NO.144 is the predicted amino acid sequence of TbH-32.

SEQ ID NO.145 is the predicted amino acid sequence of TbH-33.

SEQ ID NO: 146-151 are PCR primers used in the preparation of a fusionprotein containing TbRa3, 38 kD and Tb38-1.

SEQ ID NO: 152 is the DNA sequence of the fusion protein containingTbRa3, 38 kD and Tb38-1.

SEQ ID NO: 153 is the amino acid sequence of the fusion proteincontaining TbRa3, 38 kD and Tb38-1.

SEQ ID NO: 154 is the DNA sequence of the M. tuberculosis antigen 38 kD.

SEQ ID NO: 155 is the amino acid sequence of the M. tuberculosis antigen38 kD.

SEQ ID NO: 156 is the DNA sequence of XP14.

SEQ ID NO: 157 is the DNA sequence of XP24.

SEQ ID NO: 158 is the DNA sequence of XP31.

SEQ ID NO: 159 is the 5′ DNA sequence of XP32.

SEQ ID NO: 160 is the 3′ DNA sequence of XP32.

SEQ ID NO: 161 is the predicted amino acid sequence of XP14.

SEQ ID NO: 162 is the predicted amino acid sequence encoded by thereverse complement of XP14.

SEQ ID NO: 163 is the DNA sequence of XP27.

SEQ ID NO: 164 is the DNA sequence of XP36.

SEQ ID NO: 165 is the 5′ DNA sequence of XP4.

SEQ ID NO: 166 is the 5′ DNA sequence of XP5.

SEQ ID NO: 167 is the 5′ DNA sequence of XP17.

SEQ ID NO: 168 is the 5′ DNA sequence of XP30.

SEQ ID NO: 169 is the 5′ DNA sequence of XP2.

SEQ ID NO: 170 is the 3′ DNA sequence of XP2.

SEQ ID NO: 171 is the 5′ DNA sequence of XP3.

SEQ ID NO: 172 is the 3′ DNA sequence of XP3.

SEQ ID NO: 173 is the 5′ DNA sequence of XP6.

SEQ ID NO: 174 is the 3′ DNA sequence of XP6.

SEQ ID NO: 175 is the 5′ DNA sequence of XP18.

SEQ ID NO: 176 is the 3′ DNA sequence of XP18.

SEQ ID NO: 177 is the 5′ DNA sequence of XP19.

SEQ ID NO: 178 is the 3′ DNA sequence of XP19.

SEQ ID NO: 179 is the 5′ DNA sequence of XP22.

SEQ ID NO: 180 is the 3′ DNA sequence of XP22.

SEQ ID NO: 181 is the 5′ DNA sequence of XP25.

SEQ ID NO: 182 is the 3′ DNA sequence of XP25.

SEQ ID NO: 183 is the full-length DNA sequence of TbH4-XP1.

SEQ ID NO: 184 is the predicted amino acid sequence of TbH4-XP1.

SEQ ID NO: 185 is the predicted amino acid sequence encoded by thereverse complement of TbH4-XP1.

SEQ ID NO: 186 is a first predicted amino acid sequence encoded by XP36.

SEQ ID NO: 187 is a second predicted amino acid sequence encoded byXP36.

SEQ ID NO: 188 is the predicted amino acid sequence encoded by thereverse complement of XP36.

SEQ ID NO: 189 is the DNA sequence of RDIF2.

SEQ ID NO: 190 is the DNA sequence of RDIF5.

SEQ ID NO: 191 is the DNA sequence of RDIF8.

SEQ ID NO: 192 is the DNA sequence of RDIF10.

SEQ ID NO: 193 is the DNA sequence of RDIF11.

SEQ ID NO: 194 is the predicted amino acid sequence of RDIF2.

SEQ ID NO: 195 is the predicted amino acid sequence of RDIF5.

SEQ ID NO: 196 is the predicted amino acid sequence of RDIF8.

SEQ ID NO: 197 is the predicted amino acid sequence of RDIF10.

SEQ ID NO: 198 is the predicted amino acid sequence of RDIF11.

SEQ ID NO: 199 is the 5′ DNA sequence of RDIF12.

SEQ ID NO: 200 is the 3′ DNA sequence of RDIF12.

SEQ ID NO: 201 is the DNA sequence of RDIF7.

SEQ ID NO: 202 is the predicted amino acid sequence of RDIF7.

SEQ ID NO: 203 is the DNA sequence of DIF2-1.

SEQ ID NO: 204 is the predicted amino acid sequence of DIF2-1.

SEQ ID NO: 205-212 are PCR primers used in the preparation of a fusionprotein containing TbRa3, 38 kD. Tb38-1 and DPEP (hereinafter referredto as TbF-2).

SEQ ID NO: 213 is the DNA sequence of the fusion protein TbF-2.

SEQ ID NO: 214 is the amino acid sequence of the fusion protein TbF-2.

SEQ ID NO:215 is the 5′ DNA sequence of MO-1.

SEQ ID NO:216 is the 5′ DNA sequence for MO-2

SEQ ID NO:217 is the 5′ DNA sequence for MO-4.

SEQ ID NO:218 is the 5′ DNA sequence for MO-8.

SEQ ID NO:219 is the 5′ DNA sequence for MO-9.

SEQ ID NO:220 is the 5′ DNA sequence for MO-26.

SEQ ID NO:221 is the 5′ DNA sequence for MO-28.

SEQ ID NO:222 is the 5′ DNA sequence for MO-29.

SEQ ID NO:223 is the 5′ DNA sequence for MO-30.

SEQ ID NO:224 is the 5′ DNA sequence for MO-34.

SEQ ID NO:225 is the 5′ DNA sequence for MO-35.

SEQ ID NO:226 is the predicted amino acid sequence for MO-1.

SEQ ID NO:227 is the predicted amino acid sequence for MO-2.

SEQ ID NO:228 is the predicted amino acid sequence for MO-4.

SEQ ID NO:229 is the predicted amino acid sequence for MO-8.

SEQ ID NO:230 is the predicted amino acid sequence for MO-9.

SEQ ID NO:231 is the predicted amino acid sequence for MO-26.

SEQ ID NO:232 is the predicted amino acid sequence for MO-28.

SEQ ID NO:233 is the predicted amino acid sequence for MO-29.

SEQ ID NO:234 is the predicted amino acid sequence for MO-30.

SEQ ID NO:235 is the predicted amino acid sequence for MO-34.

SEQ ID NO:236 is the predicted amino acid sequence for MO-35.

SEQ ID NO:237 is the determined DNA sequence for MO-10.

SEQ ID NO:238 is the predicted amino acid sequence for MO-10.

SEQ ID NO:239 is the 3′ DNA sequence for MO-27.

SEQ ID NO:240 is the full-length DNA sequence for DPPD.

SEQ ID NO:241 is the predicted full-length amino acid sequence for DPPD.

SEQ ID NO:242 is the determined 5′ cDNA sequence for LSER-10

SEQ ID NO:243 is the determined 5′ cDNA sequence for LSER-11

SEQ ID NO:244 is the determined 5′ cDNA sequence for LSER-12

SEQ ID NO:245 is the determined 5′ cDNA sequence for LSER-13

SEQ ID NO:246 is the determined 5′ cDNA sequence for LSER-16

SEQ ID NO:247 is the determined 5′ cDNA sequence for LSER-25

SEQ ID NO:248 is the predicted amino acid sequence for LSER-10

SEQ ID NO:249 is the predicted amino acid sequence for LSER-12

SEQ ID NO:250 is the predicted amino acid sequence for LSER-13

SEQ ID NO:251 is the predicted amino acid sequence for LSER-16

SEQ ID NO:252 is the predicted amino acid sequence for LSER-25

SEQ ID NO:253 is the determined cDNA sequence for LSER-18

SEQ ID NO:254 is the determined cDNA sequence for LSER-23

SEQ ID NO:255 is the determined cDNA sequence for LSER-24

SEQ ID NO:256 is the determined cDNA sequence for LSER-27

SEQ ID NO:257 is the predicted amino acid sequence for LSER-18

SEQ ID NO:258 is the predicted amino acid sequence for LSER-23

SEQ ID NO:259 is the predicted amino acid sequence for LSER-24

SEQ ID NO:260 is the predicted amino acid sequence for LSER-27

SEQ ID NO:261 is the determined 5′ cDNA sequence for LSER-1

SEQ ID NO:262 is the determined 5′ cDNA sequence for LSER-3

SEQ ID NO:263 is the determined 5′ cDNA sequence for LSER-4

SEQ ID NO:264 is the determined 5′ cDNA sequence for LSER-5

SEQ ID NO:265 is the determined 5′ cDNA sequence for LSER6

SEQ ID NO:266 is the determined 5′ cDNA sequence for LSER-8

SEQ ID NO:267 is the determined 5′ cDNA sequence for LSER-14

SEQ ID NO:268 is the determined 5′ cDNA sequence for LSER-15

SEQ ID NO:269 is the determined 5′ cDNA sequence for LSER-17

SEQ ID NO:270 is the determined 5′ cDNA sequence for LSER-19

SEQ ID NO:271 is the determined 5′ cDNA sequence for LSER-20

SEQ ID NO:272 is the determined 5′ cDNA sequence for LSER-22

SEQ ID NO:273 is the determined 5′ cDNA sequence for LSER-26

SEQ ID NO:274 is the determined 5′ cDNA sequence for LSER-28

SEQ ID NO:275 is the determined 5′ cDNA sequence for LSER-29

SEQ ID NO:276 is the determined 5′ cDNA sequence for LSER-30

SEQ ID NO:277 is the predicted amino acid sequence for LSER-1

SEQ ID NO:278 is the predicted amino acid sequence for LSER-3

SEQ ID NO:279 is the predicted amino acid sequence for LSER-5

SEQ ID NO:280 is the predicted amino acid sequence for LSER-6

SEQ ID NO:281 is the predicted amino acid sequence for LSER-8

SEQ ID NO:282 is the predicted amino acid sequence for LSER-14

SEQ ID NO:283 is the predicted amino acid sequence for LSER-15

SEQ ID NO:284 is the predicted amino acid sequence for LSER-17

SEQ ID NO:285 is the predicted amino acid sequence for LSER-19

SEQ ID NO:286 is the predicted amino acid sequence for LSER-20

SEQ ID NO:287 is the predicted amino acid sequence for LSER-22

SEQ ID NO:288 is the predicted amino acid sequence for LSER-26

SEQ ID NO:289 is the predicted amino acid sequence for LSER-28

SEQ ID NO:290 is the predicted amino acid sequence for LSER-29

SEQ ID NO:291 is the predicted amino acid sequence for LSER-30

SEQ ID NO:292 is the determined cDNA sequence for LSER-9

SEQ ID NO:293 is the determined cDNA sequence for the reverse complementof LSER-6

SEQ ID NO:294 is the predicted amino acid sequence for the reversecomplement of LSER-6

SEQ ID NO:295 is the determined 5′ cDNA sequence for MO-12

SEQ ID NO:296 is the determined 5′ cDNA sequence for MO-13

SEQ ID NO:297 is the determined 5′ cDNA sequence for MO-19

SEQ ID NO:298 is the determined 5′ cDNA sequence for MO-39

SEQ ID NO:299 is the predicted amino acid sequence for MO-12

SEQ ID NO:300 is the predicted amino acid sequence for MO-13

SEQ ID NO:301 is the predicted amino acid sequence for MO-19

SEQ ID NO:302 is the predicted amino acid sequence for MO-39

SEQ ID NO:303 is the determined 5′ cDNA sequence for Erdsn1

SEQ ID NO:304 is the determined 5′ cDNA sequence for Erdsn-2

SEQ ID NO:305 is the determined 5′ cDNA sequence for Erdsn-4

SEQ ID NO:306 is the determined 5′ cDNA sequence for Erdsn-5

SEQ ID NO:307 is the determined 5′ cDNA sequence for Erdsn-6

SEQ ID NO:308 is the determined 5′ cDNA sequence for Erdsn-7

SEQ ID NO:309 is the determined 5′ cDNA sequence for Erdsn-8

SEQ ID NO:310 is the determined 5′ cDNA sequence for Erdsn-9

SEQ ID NO:311 is the determined 5′ cDNA sequence for Erdsn-10

SEQ ID NO:312 is the determined 5′ cDNA sequence for Erdsn-12

SEQ ID NO:313 is the determined 5′ cDNA sequence for Erdsn-13

SEQ ID NO:314 is the determined 5′ cDNA sequence for Erdsn-14

SEQ ID NO:315 is the determined 5′ cDNA sequence for Erdsn-15

SEQ ID NO:316 is the determined 5′ cDNA sequence for Erdsn-16

SEQ ID NO:317 is the determined 5′ cDNA sequence for Erdsn-17

SEQ ID NO:318 is the determined 5′ cDNA sequence for Erdsn-18

SEQ ID NO:319 is the determined 5′ cDNA sequence for Erdsn-21

SEQ ID NO:320 is the determined 5′ cDNA sequence for. Erdsn-22

SEQ ID NO:321 is the determined 5′ cDNA sequence for Erdsn-23

SEQ ID NO:322 is the determined 5′ cDNA sequence for Erdsn-25

SEQ ID NO:323 is the determined 3′ cDNA sequence for Erdsn-1

SEQ ID NO:324 is the determined 3′ cDNA sequence for Erdsn-2

SEQ ID NO:325 is the determined 3′ cDNA sequence for Erdsn-4

SEQ ID NO:326 is the determined 3′ cDNA sequence for Erdsn-5

SEQ ID NO:327 is the determined 3′ cDNA sequence for Erdsn-7

SEQ ID NO:328 is the determined 3′ cDNA sequence for Erdsn-8

SEQ ID NO:329 is the determined 3′ cDNA sequence for Erdsn-9

SEQ ID NO:330 is the determined 3′ cDNA sequence for Erdsn-10

SEQ ID NO:331 is the determined 3′ cDNA sequence for Erdsn-12

SEQ ID NO:332 is the determined 3′ cDNA sequence for Erdsn-13

SEQ ID NO:333 is the determined 3′ cDNA sequence for Erdsn-14

SEQ ID NO:334 is the determined 3′ cDNA sequence for Erdsn-15

SEQ ID NO:335 is the determined 3′ cDNA sequence for Erdsn-16

SEQ ID NO:336 is the determined 3′ cDNA sequence for Erdsn-17

SEQ ID NO:337 is the determined 3′ cDNA sequence for Erdsn-18

SEQ ID NO:338 is the determined 3′ cDNA sequence for Erdsn-21

SEQ ID NO:339 is the determined 3′ cDNA sequence for Erdsn-22

SEQ ID NO:340 is the determined 3′ cDNA sequence for Erdsn-23

SEQ ID NO:341 is the determined 3′ cDNA sequence for Erdsn-25

SEQ ID NO:342 is the determined cDNA sequence for Erdsn-24

SEQ ID NO:343 is the determined amino acid sequence for a M.tuberculosis 85b precursor homolog

SEQ ID NO:344 is the determined amino acid sequence for spot 1

SEQ ID NO:345 is a determined amino acid sequence for spot 2

SEQ ID NO:346 is a determined amino acid sequence for spot 2

SEQ ID NO:347 is the determined amino acid seq for spot 4

SEQ ID NO:348 is the sequence of primer PDM-157

SEQ ID NO:349 is the sequence of primer PDM-160

SEQ ID NO:350 is the DNA sequence of the fusion protein TbF-6

SEQ ID NO:351 is the amino acid sequence of fusion protein TbF-6

SEQ ID NO:352 is the sequence of primer PDM-176

SEQ ID NO:353 is the sequence of primer PDM-175

SEQ ID NO:354 is the DNA sequence of the fusion protein TbF-8

SEQ ID NO:355 is the amino acid sequence of the fusion protein TbF-8

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed tocompositions and methods for preventing, treating and diagnosingtuberculosis. The compositions of the subject invention includepolypeptides that comprise at least one immunogenic portion of a M.tuberculosis antigen, or a variant of such an antigen that differs onlyin conservative substitutions and/or modifications. Polypeptides withinthe scope of the present invention include, but are not limited to,immunogenic soluble M. tuberculosis antigens. A “soluble M. tuberculosisantigen” is a protein of M. tuberculosis origin that is present in M.tuberculosis culture filtrate. As used herein, the term “polypeptide”encompasses amino acid chains of any length, including full lengthproteins (i e., antigens), wherein the amino acid residues are linked bycovalent peptide bonds. Thus, a polypeptide comprising an immunogenicportion of one of the above antigens may consist entirely of theimmunogenic portion, or may contain additional sequences. The additionalsequences may be derived from the native M. tuberculosis antigen or maybe heterologous, and such sequences may (but need not) be immunogenic.

“Immunogenic,” as used herein, refers to the ability to elicit an immuneresponse (e.g., cellular) in a patient, such as a human, and/or in abiological sample. In particular, antigens that are immunogenic (andimmunogenic portions or other variants of such antigens) are capable ofstimulating cell proliferation, interleukin-12 production and/orinterferon-γ production in biological samples comprising one or morecells selected from the group of T cells, NK cells, B cells andmacrophages, where the cells are derived from an M. tuberculosis-immuneindividual. Polypeptides comprising at least an immunogenic portion ofone or more M. tuberculosis antigens may generally be used to detecttuberculosis or to induce protective immunity against tuberculosis in apatient.

The compositions and methods of the present invention also encompassvariants of the above polypeptides and DNA molecules. A polypeptide“variant,” as used herein, is a polypeptide that differs from therecited polypeptide only in conservative substitutions and/ormodifications, such that the therapeutic, antigenic and/or immunogenicproperties of the polypeptide are retained. Polypeptide variantspreferably exhibit at least about 70%, more preferably at least about90% and most preferably at least about 95% identity to the identifiedpolypeptides. For polypeptides with immunoreactive properties, variantsmay, alternatively, be identified by modifying the amino acid sequenceof one of the above polypeptides, and evaluating the immunoreactivity ofthe modified polypeptide. For polypeptides useful for the generation ofdiagnostic binding agents, a variant may be identified by evaluating amodified polypeptide for the ability to generate antibodies that detectthe presence or absence of tuberculosis. Such modified sequences may beprepared and tested using, for example, the representative proceduresdescribed herein.

As used herein, a “conservative substitution” is one in which an aminoacid is substituted for another amino acid that has similar properties,such that one skilled in the art of peptide chemistry would expect thesecondary structure and hydropathic nature of the polypeptide to besubstantially unchanged. In general, the following groups of amino acidsrepresent conservative changes: (1) ala, pro, gly, glu, asp, gin, asn,ser, thr; (2) cys, ser, tyr, thr, (3) vat, ile, leu, met, ala, phe; (4)lys, arg, his; and (5) phe, tyr, trp, his.

Variants may also, or alternatively, contain other modifications,including the deletion or addition of amino acids that have minimalinfluence on the antigenic properties, secondary structure andhydropathic nature of the polypeptide. For example, a polypeptide may beconjugated to a signal (or leader) sequence at the N-terminal end of theprotein which co-translationally or post-translationally directstransfer of the protein. The polypeptide may also be conjugated to alinker or other sequence for ease of synthesis, purification oridentification of the polypeptide (e.g., poly-His), or to enhancebinding of the polypeptide to a solid support. For example, apolypeptide may be conjugated to an immunoglobulin Fc region.

A nucleotide “variant” is a sequence that differs from the recitednucleotide sequence in having one or more nucleotide deletions,substitutions or additions. Such modifications may be readily introducedusing standard mutagenesis techniques, such as oligonucleotide-directedsite-specific mutagenesis as taught, for example, by Adelman et al.(DNA, 2:183, 1983). Nucleotide variants may be naturally occurringallelic variants, or non-naturally occurring variants. Variantnucleotide sequences preferably exhibit at least about 70%, morepreferably at least about 80% and most preferably at least about 90%identity to the recited sequence. Such variant nucleotide sequences willgenerally hybridize to the recite nucleotide sequence under stringentconditions. As used herein, “stringent conditions” refers to prewashingin a solution of 6×SSC, 0.2% SDS; hybridizing at 65° C., 6×SSC, 0.2% SDSovernight; followed by two washes of 30 minutes each in 1×SSC, 0.1% SDSat 65° C. and two washes of 30 minutes each in 0.2×SSC, 0.1% SDS at 65°C.

In a related aspect, combination polypeptides are disclosed. A“combination polypeptide” is a polypeptide comprising at least one ofthe above immunogenic portions and one or more additional immunogenic M.tuberculosis sequences, which are joined via a peptide linkage into asingle amino acid chain. The sequences may be joined directly (i.e.,with no intervening amino acids) or may be joined by way of a linkersequence (e.g., Gly-Cys-Gly) that does not significantly diminish theimmunogenic properties of the component polypeptides.

In general, M. tuberculosis antigens, and DNA sequences encoding suchantigens, may be prepared using any of a variety of procedures. Forexample, soluble antigens may be isolated from M. tuberculosis culturefiltrate by procedures known to those of ordinary skill in the art,including anion-exchange and reverse phase chromatography. Purifiedantigens are then evaluated for their ability to elicit an appropriateimmune response (e.g., cellular) using, for example, the representativemethods described herein. Immunogenic antigens may then be partiallysequenced using techniques such as traditional Edman chemistry. SeeEdman and Berg, Eur. J. Biochem 80:116-132, 1967.

Immunogenic antigens may also be produced recombinantly using a DNAsequence that encodes the antigen, which has been inserted into anexpression vector and expressed in an appropriate host. DNA moleculesencoding soluble antigens may be isolated by screening an appropriate M.tuberculosis expression library with anti-sera (e.g., rabbit) raisedspecifically against soluble M. tuberculosis antigens. DNA sequencesencoding antigens that may or may not be soluble may be identified byscreening an appropriate M. tuberculosis genomic or cDNA expressionlibrary with sera obtained from patients infected with M. tuberculosis.Such screens may generally be performed using techniques well known tothose of ordinary skill in the art, such as those described in Sambrooket al., Molecular Cloning: A Laboratory Manual, Cold Spring HarborLaboratories, Cold Spring Harbor, N.Y., 1989.

DNA sequences encoding soluble antigens may also be obtained byscreening an appropriate M. tuberculosis cDNA or genomic DNA library forDNA sequences that hybridize to degenerate oligonucleotides derived frompartial amino acid sequences of isolated soluble antigens Degenerateoligonucleotide sequences for use in such a screen may be designed andsynthesized, and the screen may be performed, as described (for example)in Sambrook et al., Molecular Cloning: A Laboratory Manual Cold SpringHarbor Laboratories, Cold Spring Harbor, N.Y., 1989 (and referencescited therein). Polymerase chain reaction (PCR) may also be employed,using the above oligonucleotides in methods well known in the art, toisolate a nucleic acid probe from a cDNA or genomic library. The libraryscreen may then be performed using the isolated probe.

Alternatively, genomic or cDNA libraries derived from M. tuberculosismay be screened directly using peripheral blood mononuclear cells(PBMCs) or T cell lines or clones derived from one or more M.tuberculosis-immune individuals. In general, PBMCs and/or T cells foruse in such screens may be prepared as described below. Direct libraryscreens may generally be performed by assaying pools of expressedrecombinant proteins for the ability to induce proliferation and/orinterferon-γ production in T cells derived from an M.tuberculosis-immune individual. Alternatively, potential T cell antigensmay be first selected based on antibody reactivity, as described above.

Regardless of the method of preparation, the antigens (and immunogenicportions thereof) described herein (which may or may not be soluble)have the ability to induce an immunogenic response. More specifically,the antigens have the ability to induce proliferation and/or cytokineproduction (i.e., interferon-γ and/or interleukin-12 production) in Tcells, NK cells, B cells and/or macrophages derived from an M.tuberculosis-immune individual. The selection of cell type for use inevaluating an immunogenic response to a antigen will, of course, dependon the desired response. For example, interleukin-12 production is mostreadily evaluated using preparations containing B cells and/ormacrophages. An M. tuberculosis-immune individual is one who isconsidered to be resistant to the development of tuberculosis by virtueof having mounted an effective T cell response to M. tuberculosis (i.e.,substantially free of disease symptoms). Such individuals may beidentified based on a strongly positive (i.e., greater than about 10 mmdiameter induration) intradermal skin test response to tuberculosisproteins (PPD) and an absence of any signs or symptoms of tuberculosisdisease. T cells, NK cells, B cells and macrophages derived from M.tuberculosis-immune individuals may be prepared using methods known tothose of ordinary skill in the art. For example, a preparation of PBMCs(i e., peripheral blood mononuclear cells) may be employed withoutfurther separation of component cells PBMCs may generally be prepared,for example, using density centrifugation through Ficoll™ (WinthropLaboratories, NY). T cells for use in the assays described herein mayalso be purified directly from PBMCs. Alternatively, an enriched T cellline reactive against mycobacterial proteins, or T cell clones reactiveto individual mycobacterial proteins, may be employed. Such T cellclones may be generated by, for example, culturing PBMCs from M.tuberculosis-immune individuals with mycobacterial proteins for a periodof 2-4 weeks This allows expansion of only the mycobacterialprotein-specific T cells, resulting in a line composed solely of suchcells. These cells may then be cloned and tested with individualproteins, using methods known to those of ordinary skill in the art, tomore accurately define individual T cell specificity. In general,antigens that test positive in assays for proliferation and/or cytokineproduction (i.e., interferon-γ and/or interleukin-12 production)performed using T cells, NK cells, B cells and/or macrophages derivedfrom an M. tuberculosis-immune individual are considered immunogenic.Such assays may be performed, for example, using the representativeprocedures described below. Immunogenic portions of such antigens may beidentified using similar assays, and may be present within thepolypeptides described herein.

The ability of a polypeptide (e.g., an immunogenic antigen, or a portionor other variant thereof) to induce cell proliferation is evaluated bycontacting the cells (e.g., T cells and/or NK cells) with thepolypeptide and measuring the proliferation of the cells. In general,the amount of polypeptide that is sufficient for evaluation of about 10⁵cells ranges from about 10 ng/mL to about 100 μg/mL and preferably isabout 10 μg/mL. The incubation of polypeptide with cells is typicallyperformed at 37° C. for about six days. Following incubation withpolypeptide, the cells are assayed for a proliferative response, whichmay be evaluated by methods known to those of ordinary skill in the art,such as exposing cells to a pulse of radiolabeled thymidine andmeasuring the incorporation of label into cellular DNA. In general, apolypeptide that results in at least a three fold increase inproliferation above background (i.e. the proliferation observed forcells cultured without polypeptide) is considered to be able to induceproliferation.

The ability of a polypeptide to stimulate the production of interferon-γand/or interleukin-12 in cells may be evaluated by contacting the cellswith the polypeptide and measuring the level of interferon-γ orinterleukin-12 produced by the cells. In general, the amount ofpolypeptide that is sufficient for the evaluation of about 10⁵ cellsranges from about 10 ng/mL to about 100 μg/mL and preferably is about 10μg/mL. The polypeptide may, but need not, be immobilized on a solidsupport, such as a bead or a biodegradable microsphere, such as thosedescribed in U.S. Pat. Nos. 4,897,268 and 5,075,109 The incubation ofpolypeptide with the cells is typically performed at 37° C. for aboutsix days. Following incubation with polypeptide, the cells are assayedfor interferon-γ and/or interleukin-12 (or one or more subunitsthereof), S which may be evaluated by methods known to those of ordinaryskill in the art, such as an enzyme-linked immunosorbent assay (ELISA)or, in the case of IL-12 P70 subunit, a bioassay such as an assaymeasuring proliferation of T cells. In general, a polypeptide thatresults in the production of at least 50 pg of interferon-γ per mL ofcultured supernatant (containing 10⁴-10⁵ T cells per mL) is consideredable to stimulate the production of interferon-γ. A polypeptide thatstimulates the production of at least 10 pg/mL of IL-12 P70 subunit,and/or at least 100 pg/mL of IL-12 P40 subunit, per 10⁵ macrophages or Bcells (or per 3×10⁵ PBMC) is considered able to stimulate the productionof IL-12.

In general, immunogenic antigens are those antigens that stimulateproliferation and/or cytokine production (i.e., interferon-γ and/orinterleukin-12 production) in T cells, NK cells, B cells and/ormacrophages derived from at least about 25% of M. tuberculosis-immuneindividuals Among these immunogenic antigens, polypeptides havingsuperior therapeutic properties may be distinguished based on themagnitude of the responses in the above assays and based on thepercentage of individuals for which a response is observed. In addition,antigens having superior therapeutic properties will not stimulateproliferation and/or cytokine production in vitro in cells derived frommore than about 25% of individuals that are not M. tuberculosis-immune,thereby eliminating responses that are not specifically due to M.tuberculosis-responsive cells. Those antigens that induce a response ina high percentage of T cell, NK cell, B cell and/or macrophagepreparations from M. tuberculosis-immune individuals (with a lowincidence of responses in cell preparations from other individuals) havesuperior therapeutic properties.

Antigens with superior therapeutic properties may also be identifiedbased on their ability to diminish the severity of M. tuberculosisinfection in experimental animals, when administered as a vaccine.Suitable vaccine preparations for use on experimental animals aredescribed in detail below. Efficacy may be determined based on theability of the antigen to provide at least about a 50% reduction inbacterial numbers and/or at least about a 40% decrease in mortalityfollowing experimental infection. Suitable experimental animals includemice, guinea pigs and primates.

Antigens having superior diagnostic properties may generally beidentified based on the ability to elicit a response in an intradermalskin test performed on an individual with active tuberculosis, but notin a test performed on an individual who is not infected with M.tuberculosis. Skin tests may generally be performed as described below,with a response of at least 5 mm induration considered positive.

Immunogenic portions of the antigens described herein may be preparedand identified using well known techniques, such as those summarized inPaul, Fundamental Immunology, 3d ed., Raven Press, 1993, pp. 243-247 andreferences cited therein. Such techniques include screening polypeptideportions of the native antigen for immunogenic properties. Therepresentative proliferation and cytokine production assays describedherein may generally be employed in these screens. An immunogenicportion of a polypeptide is a portion that, within such representativeassays, generates an immune response (e.g., proliferation, interferon-γproduction and/or interleukin-12 production) that is substantiallysimilar to that generated by the full length antigen. In other words, animmunogenic portion of an antigen may generate at least about 20%, andpreferably about 100%, of the proliferation induced by the full lengthantigen in the model proliferation assay described herein. Animmunogenic portion may also, or alternatively, stimulate the productionof at least about 20%, and preferably about 100%, of the interferon-γand/or interleukin-12 induced by the full length antigen in the modelassay described herein.

Portions and other variants of M. tuberculosis antigens may be generatedby synthetic or recombinant means. Synthetic polypeptides having fewerthan about 100 amino acids, and generally fewer than about 50 aminoacids, may be generated using techniques well known to those of ordinaryskill in the art. For example, such polypeptides may be synthesizedusing any of the commercially available solid-phase techniques, such asthe Merrifield solid-phase synthesis method, where amino acids aresequentially added to a growing amino acid chain. See Merrifield, J. Am.Chem. Soc. 85:2149-2146, 1963. Equipment for automated synthesis ofpolypeptides is commercially available from suppliers such as AppliedBioSystems, Inc., Foster City, Calif., and may be operated according tothe manufacturer's instructions. Variants of a native antigen maygenerally be prepared using standard mutagenesis techniques, such asoligonucleotide-directed site-specific mutagenesis. Sections of the DNAsequence may also be removed using standard techniques to permitpreparation of truncated polypeptides.

Recombinant polypeptides containing portions and/or variants of a nativeantigen may be readily prepared from a DNA sequence encoding thepolypeptide using a variety of techniques well known to those ofordinary skill in the art. For example, supernatants from suitablehost/vector systems which secrete recombinant protein into culture mediamay be first concentrated using a commercially available filter.Following concentration, the concentrate may be applied to a suitablepurification matrix such as an affinity matrix or an ion exchange resin.Finally, one or more reverse phase HPLC steps can be employed to furtherpurify a recombinant protein.

Any of a variety of expression vectors known to those of ordinary skillin the art may be employed to express recombinant polypeptides of thisinvention. Expression may be achieved in any appropriate host cell thathas been transformed or transfected with an expression vector containinga DNA molecule that encodes a recombinant polypeptide. Suitable hostcells include prokaryotes, yeast and higher eukaryotic cells.Preferably, the host cells employed are E. coli, yeast or a mammaliancell line such as COS or CHO. The DNA sequences expressed in this mannermay encode naturally occurring antigens, portions of naturally occurringantigens, or other variants thereof.

In general, regardless of the method of preparation, the polypeptidesdisclosed herein are prepared in substantially pure form. Preferably,the polypeptides are at least about 80% pure, more preferably at leastabout 90% pure and most preferably at least about 99% pure. In certainpreferred embodiments, described in detail below, the substantially purepolypeptides are incorporated into pharmaceutical compositions orvaccines for use in one or more of the methods disclosed herein.

In certain specific embodiments, the subject invention disclosespolypeptides comprising at least an immunogenic portion of a soluble M.tuberculosis antigen having one of the following N-terminal sequences,or a variant thereof that differs only in conservative substitutionsand/or modifications:

(a) (SEQ ID No. 120) Asp-Pro-Val-Asp-Ala-Val-Ile-Asn-Thr-Thr-Cys-Asn-Tyr-Gly-Gln-Val-Val-Ala-Ala-Leu; (b) (SEQ ID No. 121)Ala-Val-Glu-Ser-Gly-Met-Leu-Ala-Leu-Gly-Thr-Pro- Ala-Pro-Ser; (c) (SEQID No. 122) Ala-Ala-Met-Lys-Pro-Arg-Thr-Gly-Asp-Gly-Pro-Leu-Glu-Ala-Ala-Lys-Glu-Gly-Arg; (d) (SEQ ID No. 123)Tyr-Tyr-Trp-Cys-Pro-Gly-Gln-Pro-Phe-Asp-Pro-Ala- Trp-Gly-Pro; (e) (SEQID No. 124) Asp-Ile-Gly-Ser-Glu-Ser-Thr-Glu-Asp-Gln-Gln-Xaa- Ala-Val;(f) (SEQ ID No. 125) Ala-Glu-Glu-Ser-Ile-Ser-Thr-Xaa-Glu-Xaa-Ile-Val-Pro; (g) (SEQ ID No. 126)Asp-Pro-Glu-Pro-Ala-Pro-Pro-Val-Pro-Thr-Ala-Ala- Ala-Ser-Pro-Pro-Ser;(h) (SEQ ID No. 127) Ala-Pro-Lys-Thr-Tyr-Xaa-Glu-Glu-Leu-Lys-Gly-Thr-Asp-Thr-Gly; (i) (SEQ ID No. 128)Asp-Pro-Ala-Ser-Ala-Pro-Asp-Val-Pro-Thr-Ala-Ala-Gln-Leu-Thr-Ser-Leu-Leu-Asn-Ser-Leu-Ala-Asp-Pro-Asn-Val-Ser-Phe-Ala-Asn; (j) (SEQ ID No. 134)Xaa-Asp-Ser-Glu-Lys-Ser-Ala-Thr-Ile-Lys-Val-Thr- Asp-Ala-Ser; (k) (SEQID No. 135) Ala-Gly-Asp-Thr-Xaa-Ile-Tyr-Ile-Val-Gly-Asn-Leu-Thr-Ala-Asp; or (l) (SEQ ID No. 136)Ala-Pro-Glu-Ser-Gly-Ala-Gly-Leu-Gly-Gly-Thr-Val- Gln-Ala-Gly;wherein Xaa may be any amino acid, preferably a cysteine residue. A DNAsequence encoding the antigen identified as (g) above is provided in SEQID No. 52, and the polypeptide encoded by SEQ ID No. 52 is provided inSEQ ID No. 53. A DNA sequence encoding the antigen defined as (a) aboveis provided in SEQ ID No. 101; its deduced amino acid sequence isprovided in SEQ ID No. 102. A DNA sequence corresponding to antigen (d)above is provided in SEQ ID No. 24 a DNA sequence corresponding toantigen (c) is provided in SEQ ID No. 25 and a DNA sequencecorresponding to antigen (i) is provided in SEQ ID No. 99; its deducedamino acid sequence is provided in SEQ ID No. 100.

In a further specific embodiment, the subject invention disclosespolypeptides comprising at least an immunogenic portion of an M.tuberculosis antigen having one of the following N-terminal sequences,or a variant thereof that differs only in conservative substitutionsand/or modifications:

(m) (SEQ ID No 137) Xaa-Tyr-Ile-Ala-Tyr-Xaa-Thr-Thr-Ala-Gly-Ile-Val-Pro-Gly-Lys-Ile-Asn-Val-His-Leu-Val; or (n) (SEQ ID No. 129)Asp-Pro-Pro-Asp-Pro-His-Gln-Xaa-Asp-Met-Thr-Lys-Gly-Thr-Tyr-Pro-Gly-Gly-Arg-Arg-Xaa-Phe;wherein Xaa may be any amino acid, preferably a cysteine residue.

In other specific embodiments, the subject invention disclosespolypeptides comprising at least an immunogenic portion of a soluble M.tuberculosis antigen (or a variant of such an antigen) that comprisesone or more of the amino acid sequences encoded by (a) the DNA sequencesof SEQ ID Nos.: 1, 2, 4-10, 13-25 and 52; (b) the complements of suchDNA sequences, or (c) DNA sequences substantially homologous to asequence in (a) or (b).

In further specific embodiments, the subject invention disclosespolypeptides comprising at least an immunogenic portion of a M.tuberculosis antigen (or a variant of such an antigen), which may or maynot be soluble, that comprises one or more of the amino acid sequencesencoded by (a) the DNA sequences of SEQ ID Nos.: 26-51, 138, 139,163-183, 189-193, 199, 200, 201, 203, 215-225, 239, 240, 242-247,253-256, 261-276, 292, 293, 295-298 and 303-342, (b) the complements ofsuch DNA sequences or (c) DNA sequences substantially homologous to asequence in (a) or (b).

In the specific embodiments discussed above, the M. tuberculosisantigens include variants that are encoded by DNA sequences which aresubstantially homologous to one or more of DNA sequences specificallyrecited herein. “Substantial homology,” as used herein, refers to DNAsequences that are capable of hybridizing under moderately stringentconditions. Suitable moderately stringent conditions include prewashingin a solution of 5×SSC, 0.5% SDS, 1.0 mM EDTA (pH8.0); hybridizing at50° C.-65° C., 5×SSC, overnight or, in the case of cross-specieshomology at 45° C., 0.5×SSC; followed by washing twice at 65° C. for 20minutes with each of 2×, 0.5× and 0.2×SSC containing 0.1% SDS). Suchhybridizing DNA sequences are also within the scope of this invention,as are nucleotide sequences that, due to code degeneracy, encode animmunogenic polypeptide that is encoded by a hybridizing DNA sequence.

In a related aspect, the present invention provides fusion proteinscomprising a first and a second inventive polypeptide or, alternatively,a polypeptide of the present invention and a known M tuberculosisantigen, such as the 38 kD antigen described in Andersen and Hansen,Infect. Immun. 57:2481-2488, 1989, (Genbank Accession No. M30046) orESAT-6 (SEQ ID Nos. 103 and 104), together with variants of such fusionproteins. The fusion proteins of the present invention may also includea linker peptide between the first and second polypeptides.

A DNA sequence encoding a fusion protein of the present invention isconstructed using known recombinant DNA techniques to assemble separateDNA sequences encoding the first and second polypeptides into anappropriate expression vector. The 3′ end of a DNA sequence encoding thefirst polypeptide is ligated, with or without a peptide linker, to the5′ end of a DNA sequence encoding the second polypeptide so that thereading frames of the sequences are in phase to permit mRNA translationof the two DNA sequences into a single fusion protein that retains thebiological activity of both the first and the second polypeptides.

A peptide linker sequence may be employed to separate the first and thesecond polypeptides by a distance sufficient to ensure that eachpolypeptide folds into its secondary and tertiary structures. Such apeptide linker sequence is incorporated into the fusion protein usingstandard techniques well known in the art. Suitable peptide linkersequences may be chosen based on the following factors: (1) theirability to adopt a flexible extended conformation; (2) their inabilityto adopt a secondary structure that could interact with functionalepitopes on the first and second polypeptides; and (3) the lack ofhydrophobic or charged residues that might react with the polypeptidefunctional epitopes. Preferred peptide linker sequences contain Gly, Asnand Ser residues. Other near neutral amino acids, such as Thr and Alamay also be used in the linker sequence. Amino acid sequences which maybe usefully employed as linkers include those disclosed in Maratea etal., Gene 40:3946, 1985; Murphy et al., Proc. Natl. Acad. Sci. USA83:8258-8262, 1986; U.S. Pat. No. 4,935,233 and U.S. Pat. No. 4,751,180.The linker sequence may be from 1 to about 50 amino acids in length.Peptide sequences are not required when the first and secondpolypeptides have non-essential N-terminal amino acid regions that canbe used to separate the functional domains and prevent stericinterference.

The ligated DNA sequences are operably linked to suitabletranscriptional or translational regulatory elements. The regulatoryelements responsible for expression of DNA are located only 5′ to theDNA sequence encoding the first polypeptides. Similarly, stop codonsrequire to end translation and transcription termination signals areonly present 3′ to the DNA sequence encoding the second polypeptide.

In another aspect, the present invention provides methods for using oneor more of the above polypeptides or fusion proteins (or DNA moleculesencoding such polypeptides) to induce protective immunity againsttuberculosis in a patient. As used herein, a “patient” refers to anywarm-blooded animal, preferably a human. A patient may be afflicted witha disease, or may be free of detectable disease and/or infection. Inother words, protective immunity may be induced to prevent or treattuberculosis.

In this aspect, the polypeptide, fusion protein or DNA molecule isgenerally present within a pharmaceutical composition and/or a vaccine.Pharmaceutical compositions may comprise one or more polypeptides, eachof which may contain one or more of the above sequences (or variantsthereof), and a physiologically acceptable carrier. Vaccines maycomprise one or more of the above polypeptides and a non-specific immuneresponse enhancer, such as an adjuvant or a liposome (into which thepolypeptide is incorporated). Such pharmaceutical compositions andvaccines may also contain other M. tuberculosis antigens, eitherincorporated into a combination polypeptide or present within a separatepolypeptide.

Alternatively, a vaccine may contain DNA encoding one or morepolypeptides as described above, such that the polypeptide is generatedin situ. In such vaccines, the DNA may be present within any of avariety of delivery systems known to those of ordinary skill in the art,including nucleic acid expression systems, bacterial and viralexpression systems. Appropriate nucleic acid expression systems containthe necessary DNA sequences for expression in the patient (such as asuitable promoter and terminating signal). Bacterial delivery systemsinvolve the administration of a bacterium (such asBacillus-Calmette-Guerrin) that expresses an immunogenic portion of thepolypeptide on its cell surface. In a preferred embodiment, the DNA maybe introduced using a viral expression system (e.g., vaccinia or otherpox virus, retrovirus, or adenovirus), which may involve the use of anon-pathogenic (defective), replication competent virus. Techniques forincorporating DNA into such expression systems are well known to thoseof ordinary skill in the art. The DNA may also be “naked,” as described,for example, in Ulmer et al., Science 259:1745-1749, 1993 and reviewedby Cohen, Science 259:1691-1692, 1993. The uptake of naked DNA may beincreased by coating the DNA onto biodegradable beads, which areefficiently transported into the cells.

In a related aspect, a DNA vaccine as described above may beadministered simultaneously with or sequentially to either a polypeptideof the present invention or a known M. tuberculosis antigen, such as the38 kD antigen described above. For example, administration of DNAencoding a polypeptide of the present invention, either “naked” or in adelivery system as described above, may be followed by administration ofan antigen in order to enhance the protective immune effect of thevaccine.

Routes and frequency of administration, as well as dosage, will varyfrom individual to individual and may parallel those currently beingused in immunization using BCG. In general, the pharmaceuticalcompositions and vaccines may be administered by injection (e.g.,intracutaneous, intramuscular, intravenous or subcutaneous),intranasally (e.g., by aspiration) or orally. Between 1 and 3 doses maybe administered for a 1-36 week period. Preferably, 3 doses areadministered, at intervals of 3-4 months, and booster vaccinations maybe given periodically thereafter. Alternate protocols may be appropriatefor individual patients. A suitable dose is an amount of polypeptide orDNA that, when administered as described above, is capable of raising animmune response in an immunized patient sufficient to protect thepatient from M. tuberculosis infection for at least 1-2 years. Ingeneral, the amount of polypeptide present in a dose (or produced insitu by the DNA in a dose) ranges from about 1 pg to about 100 mg per kgof host, typically from about 10 pg to about 1 mg, and preferably fromabout 100 pg to about 1 μg. Suitable dose sizes will vary with the sizeof the patient, but will typically range from about 0.1 mL to about 5mL.

While any suitable carrier known to those of ordinary skill in the artmay be employed in the pharmaceutical compositions of this invention,the type of carrier will vary depending on the mode of administration.For parenteral administration, such as subcutaneous injection, thecarrier preferably comprises water, saline, alcohol, a fat, a wax or abuffer. For oral administration, any of the above carriers or a solidcarrier, such as mannitol, lactose, starch, magnesium stearate, sodiumsaccharine, talcum, cellulose, glucose, sucrose, and magnesiumcarbonate, may be employed. Biodegradable microspheres (e.g., polylacticgalactide) may also be employed as carriers for the pharmaceuticalcompositions of this invention. Suitable biodegradable microspheres aredisclosed, for example, in U.S. Pat. Nos. 4,897,268 and 5,075,109.

Any of a variety of adjuvants may be employed in the vaccines of thisinvention to nonspecifically enhance the immune response. Most adjuvantscontain a substance designed to protect the antigen from rapidcatabolism, such as aluminum hydroxide or mineral oil, and a nonspecificstimulator of immune responses, such as lipid A, Bortadella pertussis orMycobacterium tuberculosis. Suitable adjuvants are commerciallyavailable as, for example, Freund's Incomplete Adjuvant and Freund'sComplete Adjuvant (Difco Laboratories) and Merck Adjuvant 65 (Merck andCompany, Inc., Rahway, N.J.). Other suitable adjuvants include alum,biodegradable microspheres, monophosphoryl lipid A and quil A.

In another aspect, this invention provides methods for using one or moreof the polypeptides described above to diagnose tuberculosis using askin test. As used herein, a “skin test” is any assay performed directlyon a patient in which a delayed-type hypersensitivity (DTH) reaction(such as swelling, reddening or dermatitis) is measured followingintradermal injection of one or more polypeptides as described above.Such injection may be achieved using any suitable device sufficient tocontact the polypeptide or polypeptides with dermal cells of thepatient, such as a tuberculin syringe or 1 mL syringe. Preferably, thereaction is measured at least 48 hours after injection, more preferably48-72 hours.

The DTH reaction is a cell-mediated immune response, which is greater inpatients that have been exposed previously to the test antigen (i.e.,the immunogenic portion of the polypeptide employed, or a variantthereof). The response may be measured visually, using a ruler. Ingeneral, a response that is greater than about 0.5 cm in diameter,preferably greater than about 1.0 cm in diameter, is a positiveresponse, indicative of tuberculosis infection, which may or may not bemanifested as an active disease.

The polypeptides of this invention are preferably formulated, for use ina skin test, as pharmaceutical compositions containing a polypeptide anda physiologically acceptable carrier, as described above. Suchcompositions typically contain one or more of the above polypeptides inan amount ranging from about 1 μg to about 100 μg, preferably from about10 μg to about 50 μg in a volume of 0.1 mL. Preferably, the carrieremployed in such pharmaceutical compositions is a saline solution withappropriate preservatives, such as phenol and/or Tween 80™.

In a preferred embodiment, a polypeptide employed in a skin test is ofsufficient size such that it remains at the site of injection for theduration of the reaction period. In general, a polypeptide that is atleast 9 amino acids in length is sufficient. The polypeptide is alsopreferably broken down by macrophages within hours of injection to allowpresentation to T-cells. Such polypeptides may contain repeats of one ormore of the above sequences and/or other immunogenic or nonimmunogenicsequences.

The following Examples are offered by way of illustration and not by wayof limitation.

EXAMPLES Example 1 Purification and Characterization of Polypeptidesfrom M. Tuberculosis Culture Filtrate

This example illustrates the preparation of M. tuberculosis solublepolypeptides from culture filtrate. Unless otherwise noted, allpercentages in the following example are weight per volume.

M. tuberculosis (either H37Ra, ATCC No. 25177, or H37Rv, ATCC No. 25618)was cultured in sterile GAS media at 37° C. for fourteen days The mediawas then vacuum filtered (leaving the bulk of the cells) through a 0.45μfilter into a sterile 2.5 L bottle. The media was next filtered througha 0.2μ filter into a sterile 4 L bottle and NaN₃ was added to theculture filtrate to a concentration of 0.04%. The bottles were thenplaced in a 4° C. cold room.

The culture filtrate was concentrated by placing the filtrate in a 12 Lreservoir that had been autoclaved and feeding the filtrate into a 400ml Amicon stir cell which had been rinsed with ethanol and contained a10,000 kDa MWCO membrane. The pressure was maintained at 60 psi usingnitrogen gas. This procedure reduced the 12 L volume to approximately 50ml.

The culture filtrate was dialyzed into 0.1% ammonium bicarbonate using a8,000 kDa MWCO cellulose ester membrane, with two changes of ammoniumbicarbonate solution. Protein concentration was then determined by acommercially available BCA assay (Pierce, Rockford, Ill.).

The dialyzed culture filtrate was then lyophilized, and the polypeptidesresuspended in distilled water. The polypeptides were dialyzed against0.01 mM 1,3 bis[tris(hydroxymethyl)-methylamino]propane, pH7.5 (Bis-Trispropane buffer), the initial conditions for anion exchangechromatography. Fractionation was performed using gel profusionchromatography on a POROS 146 II Q/M anion exchange column 4.6 mm×100 mm(Perseptive BioSystems, Framingham, Mass.) equilibrated in 0.01 mMBis-Tris propane buffer pH7.5. Polypeptides were eluted with a linear0-0.5 M NaCl gradient in the above buffer system. The column eluent wasmonitored at a wavelength of 220 nm.

The pools of polypeptides eluting from the ion exchange column weredialyzed against distilled water and lyophilized. The resulting materialwas dissolved in 0.1% trifluoroacetic acid (TFA) pH1.9 in water, and thepolypeptides were purified on a Delta-Pak C18 column (Waters, Milford,Mass.) 300 Angstrom pore size, 5 micron particle size (3.9×150 mm). Thepolypeptides were eluted from the column with a linear gradient from0-60% dilution buffer (0.1% TFA in acetonitrile). The flow rate was 0.75ml/minute and the HPLC eluent was monitored at 214 nm. Fractionscontaining the eluted polypeptides were collected to maximize the purityof the individual samples. Approximately 200 purified polypeptides wereobtained.

The purified polypeptides were then screened for the ability to induceT-cell proliferation in PBMC preparations. The PBMCs from donors knownto be PPD skin test positive and whose T-cells were shown to proliferatein response to PPD and crude soluble proteins from MTB were cultured inmedium comprising RPMI 1640 supplemented with 10% pooled human serum and50 μg/ml gentamicin. Purified polypeptides were added in duplicate atconcentrations of 0.5 to 10 μg/mL. After six days of culture in 96-wellround-bottom plates in a volume of 200 μl, 50 μl of medium was removedfrom each well for determination of IFN-γ levels, as described below Theplates were then pulsed with 1 μCi/well of tritiated thymidine for afurther 18 hours, harvested and tritium uptake determined using a gasscintillation counter. Fractions that resulted in proliferation in bothreplicates three fold greater than the proliferation observed in cellscultured in medium alone were considered positive.

IFN-γ was measured using an enzyme-linked immunosorbent assay (ELISA).ELISA plates were coated with a mouse monoclonal antibody directed tohuman IFN-γ (PharMingen, San Diego, Calif.) in PBS for four hours atroom temperature. Wells were then blocked with PBS containing 5% (WIV)non-fat dried milk for 1 hour at room temperature. The plates were thenwashed six times in PBS/0.2% TWEEN-20 and samples diluted 1:2 in culturemedium in the ELISA plates were incubated overnight at room temperature.The plates were again washed and a polyclonal rabbit anti-human IFN-γserum diluted 1:3000 in PBS/10% normal goat serum was added to eachwell. The plates were then incubated for two hours at room temperature,washed and horseradish peroxidase-coupled anti-rabbit IgG (SigmaChemical So., St. Louis, Mo.) was added at a 1:2000 dilution in PBS/5%non-fat dried milk. After a further two hour incubation at roomtemperature, the plates were washed and TMB substrate added. Thereaction was stopped after 20 min with 1 N sulfuric acid. Opticaldensity was determined at 450 nm using 570 nm as a reference wavelength.Fractions that resulted in both replicates giving an OD two fold greaterthan the mean OD from cells cultured in medium alone, plus 3 standarddeviations, were considered positive.

For sequencing, the polypeptides were individually dried onto Biobrene™(Perkin Elmer/Applied BioSystems Division, Foster City, Calif.) treatedglass fiber filters. The filters with polypeptide were loaded onto aPerkin Elmer/Applied BioSystems Division Procise 492 protein sequencer.The polypeptides were sequenced from the amino terminal and usingtraditional Edman chemistry. The amino acid sequence was determined foreach polypeptide by comparing the retention time of the PTH amino acidderivative to the appropriate PTH derivative standards.

Using the procedure described above, antigens having the followingN-terminal sequences were isolated:

(a) (SEQ ID No. 54) Asp-Pro-Val-Asp-Ala-Val-Ile-Asn-Thr-Thr-Xaa-Asn-Tyr-Gly-Gln-Val-Val-Ala-Ala-Leu; (b) (SEQ ID No. 55)Ala-Val-Glu-Ser-Gly-Met-Leu-Ala-Leu-Gly-Thr-Pro- Ala-Pro-Ser; (c) (SEQID No. 56) Ala-Ala-Met-Lys-Pro-Arg-Thr-Gly-Asp-Gly-Pro-Leu-Glu-Ala-Ala-Lys-Glu-Gly-Arg; (d) (SEQ ID No. 57)Tyr-Tyr-Trp-Cys-Pro-Gly-Gln-Pro-Phe-Asp-Pro-Ala- Trp-Gly-Pro; (e) (SEQID No. 58) Asp-Ile-Gly-Ser-Glu-Ser-Thr-Glu-Asp-Gln-Gln-Xaa- Ala-Val; (f)(SEQ ID No. 59) Ala-Glu-Glu-Ser-Ile-Ser-Thr-Xaa-Glu-Xaa-Ile-Val- Pro;(g) (SEQ ID No. 60) Asp-Pro-Glu-Pro-Ala-Pro-Pro-Val-Pro-Ala-Ala-Ala-Ala-Pro-Pro-Ala; and (h) (SEQ ID No. 61)Ala-Pro-Lys-Thr-Tyr-Xaa-Glu-Glu-Leu-Lys-Gly-Thr- Asp-Thr-Gly;wherein Xaa may be any amino acid.

An additional antigen was isolated employing a microbore HPLCpurification step in addition to the procedure described above.Specifically, 20 μl of a fraction comprising a mixture of antigens fromthe chromatographic purification step previously described was purifiedon an Aquapore C18 column (Perkin Elmer/Applied Biosystems Division,Foster City, Calif.) with a 7 micron pore size, column size 1 mm×100 mm,in a Perkin Elmer/Applied Biosystems Division Model 172 HPLC. Fractionswere eluted from the column with a linear gradient of 1%/minute ofacetonitrile (containing 0.05% TFA) in water (0.05% TFA) at a flow rateof 80 μl/minute. The eluent was monitored at 250 nm. The originalfraction was separated into 4 major peaks plus other smaller componentsand a polypeptide was obtained which was shown to have a molecularweight of 12.054 Kd (by mass spectrometry) and the following N-terminalsequence:

(i) (SEQ ID No. 62) Asp-Pro-Ala-Ser-Ala-Pro-Asp-Val-Pro-Thr-Ala-Ala-Gln-Gln-Thr-Ser-Leu-Leu-Asn-Asn-Leu-Ala-Asp-Pro-Asp-Val-Ser-Phe-Ala-Asp.This polypeptide was shown to induce proliferation and IFN-γ productionin PBMC preparations using the assays described above.

Additional soluble antigens were isolated from M. tuberculosis culturefiltrate as follows. M. tuberculosis culture filtrate was prepared asdescribed above. Following dialysis against Bis-Tris propane buffer, atpH5.5, fractionation was performed using anion exchange chromatographyon a Poros QE column 4.6×100 mm (Perseptive Biosystems) equilibrated inBis-Tris propane buffer pH5.5. Polypeptides were eluted with a linear0-1.5 M NaCl gradient in the above buffer system at a flow rate of 10ml/min. The column eluent was monitored at a wavelength of 214 nm.

The fractions eluting from the ion exchange column were pooled andsubjected to reverse phase chromatography using a Poros R2 column4.6×100 mm (Perseptive Biosystems). Polypeptides were eluted from thecolumn with a linear gradient from 0-100% acetonitrile (0.1% TFA) at aflow rate of 5 ml/min. The eluent was monitored at 214 nm.

Fractions containing the eluted polypeptides were lyophilized andresuspended in 80 μl of aqueous 0.1% TFA and further subjected toreverse phase chromatography on a Vydac C4 column 4.6×150 mm (WesternAnalytical, Temecula, Calif.) with a linear gradient of 0-100%acetonitrile (0.1% TFA) at a flow rate of 2 ml/min. Eluent was monitoredat 214 nm.

The fraction with biological activity was separated into one major peakplus other smaller components Western blot of this peak onto PVDFmembrane revealed three major bands of molecular weights 14 Kd, 20 Kdand 26 Kd. These polypeptides were determined to have the followingN-terminal sequences, respectively:

(j) (SEQ ID No. 134) Xaa-Asp-Ser-Glu-Lys-Ser-Ala-Thr-Ile-Lys-Val-Thr-Asp-Ala-Ser; (k) (SEQ ID No. 135)Ala-Gly-Asp-Thr-Xaa-Ile-Tyr-Ile-Val-Gly-Asn-Leu- Thr-Ala-Asp; and (l)(SEQ ID No. 136) Ala-Pro-Glu-Ser-Gly-Ala-Gly-Leu-Gly-Gly-Thr-Val-Gln-Ala-Gly;,wherein Xaa may be any amino acid.Using the assays described above, these polypeptides were shown toinduce proliferation and IFN-γ production in PBMC preparations. FIGS. 1Aand B show the results of such assays using PBMC preparations from afirst and a second donor, respectively.

DNA sequences that encode the antigens designated as (a), (c), (d) and(g) above were obtained by screening a genomic M. tuberculosis libraryusing ³²P end labeled degenerate oligonucleotides corresponding to theN-terminal sequence and containing M. tuberculosis codon bias. Thescreen performed using a probe corresponding to antigen (a) aboveidentified a clone having the sequence provided in SEQ ID No. 101. Thepolypeptide encoded by SEQ ID No. 101 is provided in SEQ ID No. 102. Thescreen performed using a probe corresponding to antigen (g) aboveidentified a clone having the sequence provided in SEQ ID No. 52. Thepolypeptide encoded by SEQ ID No. 52 is provided in SEQ ID No. 53. Thescreen performed using a probe corresponding to antigen (d) aboveidentified a clone having the sequence provided in SEQ ID No. 24, andthe screen performed with a probe corresponding to antigen (c)identified a clone having the sequence provided in SEQ ID No: 25.

The above amino acid sequences were compared to known amino acidsequences in the gene bank using the DNA STAR system. The databasesearched contains some 173,000 proteins and is a combination of theSwiss, PIR databases along with translated protein sequences (Version87). No significant homologies to the amino acid sequences for antigens(a)-(h) and (l) were detected.

The amino acid sequence for antigen (i) was found to be homologous to asequence from M. leprae. The full length M. leprae sequence wasamplified from genomic DNA using the sequence obtained from GENBANK.This sequence was then used to screen the M. tuberculosis librarydescribed below in Example 2 and a full length copy of the M.tuberculosis homologue was obtained (SEQ ID No. 99).

The amino acid sequence for antigen (j) was found to be homologous to aknown M. tuberculosis protein translated from a DNA sequence. To thebest of the inventors' knowledge, this protein has not been previouslyshown to possess T-cell stimulatory activity. The amino acid sequencefor antigen (k) was found to be related to a sequence from M. leprae.

In the proliferation and IFN-γ assays described above, using three PPDpositive donors, the results for representative antigens provided aboveare presented in Table 1:

TABLE 1 RESULTS OF PBMC PROLIFERATION AND IFN-γ ASSAYS SequenceProliferation IFN-γ (a) + − (c) +++ +++ (d) ++ ++ (g) +++ +++ (h) ++++++

In Table 1, responses that gave a stimulation index (SI) of between 2and 4 (compared to cells cultured in medium alone) were scored as +, anSI of 4-8 or 2-4 at a concentration of 1 μg or less was scored as ++ andan SI of greater than 8 was scored as +++. The antigen of sequence (I)was found to have a high SI (+++) for one donor and lower SI (++ and +)for the two other donors in both proliferation and IFN-γ assays. Theseresults indicate that these antigens are capable of inducingproliferation and/or interferon-γ production.

Example 2 Use of Patient Sera to Isolate M. Tuberculosis Antigens

This example illustrates the isolation of antigens from M. tuberculosislysate by screening with serum from M. tuberculosis-infectedindividuals.

Dessicated M. tuberculosis H37Ra (Difco Laboratories) was added to a 2%NP40 solution, and alternately homogenized and sonicated three times.The resulting suspension was centrifuged at 13,000 rpm in microfugetubes and the supernatant put through a 0.2 micron syringe filter. Thefiltrate was bound to Macro Prep DEAE beads (BioRad, Hercules, Calif.).The beads were extensively washed with 20 mM Tris pH7.5 and boundproteins eluted with 1M NaCl. The 1M NaCl elute was dialyzed overnightagainst 10 mM Tris, pH7.5. Dialyzed solution was treated with DNase andRNase at 0.05 mg/ml for 30 min. at room temperature and then withα-D-mannosidase, 0.5 U/mg at pH4.5 for 3-4 hours at room temperature.After returning to pH7.5, the material was fractionated via FPLC over aBio Scale-Q-20 column (BioRad). Fractions were combined into nine pools,concentrated in a Centriprep 10 (Amicon, Beverley, Mass.) and thenscreened by Western blot for serological activity using a serum poolfrom M. tuberculosis-infected patients which was not immunoreactive withother antigens of the present invention.

The most reactive fraction was run in SDS-PAGE and transferred to PVDF.A band at approximately 85 Kd was cut out yielding the sequence:

(m) (SEQ ID No. 137) Xaa-Tyr-Ile-Ala-Tyr-Xaa-Thr-Thr-Ala-Gly-Ile-Val-Pro-Gly-Lys-Ile-Asn-Val-His-Leu-Val;,wherein Xaa may be any amino acid.

Comparison of this sequence with those in the gene bank as describedabove, revealed no significant homologies to known sequences.

A DNA sequence that encodes the antigen designated as (m) above wasobtained by screening a genomic M. tuberculosis Erdman strain libraryusing labeled degenerate oligonucleotides corresponding to theN-terminal sequence of SEQ ID NO:137. A clone was identified having theDNA sequence provided in SEQ ID NO: 203. This sequence was found toencode the amino acid sequence provided in SEQ ID NO: 204. Comparison ofthese sequences with those in the genebank revealed some similarity tosequences previously identified in M. tuberculosis and M. bovis.

Example 3 Preparation of DNA Sequences Encoding M. Tuberculosis Antigens

This example illustrates the preparation of DNA sequences encoding M.tuberculosis antigens by screening a M. tuberculosis expression librarywith sera obtained from patients infected with M. tuberculosis, or withanti-sera raised against soluble M. tuberculosis antigens.

A. Preparation of M. Tuberculosis Soluble Antigens Using RabbitAnti-Sera Raised Against M. Tuberculosis Supernatant

Genomic DNA was isolated from the M. tuberculosis strain H37Ra. The DNAwas randomly sheared and used to construct an expression library usingthe Lambda ZAP expression system (Stratagene, La Jolla, Calif.). Rabbitanti-sera was generated against secretory proteins of the M.tuberculosis strains H37Ra, H37Rv and Erdman by immunizing a rabbit withconcentrated supernatant of the M. tuberculosis cultures. Specifically,the rabbit was first immunized subcutaneously with 200 μg of proteinantigen in a total volume of 2 ml containing 10 μg muramyl dipeptide(Calbiochem, La Jolla, Calif.) and 1 ml of incomplete Freund's adjuvantFour weeks later the rabbit was boosted subcutaneously with 100 μgantigen in incomplete Freund's adjuvant. Finally, the rabbit wasimmunized intravenously four weeks later with 50 μg protein antigen. Theanti-sera were used to screen the expression library as described inSambrook et al., Molecular Cloning: A Laboratory Manual, Cold SpringHarbor Laboratories, Cold Spring Harbor, N.Y., 1989. Bacteriophageplaques expressing immunoreactive antigens were purified. Phagemid fromthe plaques was rescued and the nucleotide sequences of the M.tuberculosis clones deduced.

Thirty two clones were purified. Of these, 25 represent sequences thathave not been previously identified in human M. tuberculosis.Recombinant antigens were expressed and purified antigens used in theimmunological analysis described in Example 1. Proteins were induced byIPTG and purified by gel elution, as described in Skeiky et al., J. Exp.Med. 181:1527-1537, 1995. Representative sequences of DNA moleculesidentified in this screen are provided in SEQ ID Nos.: 1-25. Thecorresponding predicted amino acid sequences are shown in SEQ ID Nos.63-87.

On comparison of these sequences with known sequences in the gene bankusing the databases described above, it was found that the clonesreferred to hereinafter as TbRA2A, TbRA16, TbRA18, and TbRA29 (SEQ IDNos. 76, 68, 70, 75) show some homology to sequences previouslyidentified in Mycobacterium leprae but not in M. tuberculosis TbRA2A wasfound to be a lipoprotein, with a six residue lipidation sequence beinglocated adjacent to a hydrophobic secretory sequence TbRA11, TbRA26,TbRA28 and TbDPEP (SEQ ID Nos.: 65, 73, 74, 53) have been previouslyidentified in M. tuberculosis. No significant homologies were found toTbRA1, TbRA3, TbRA4, TbRA9, TbRA10, TbRA13, TbRA17, TbRa19, TbRA29,TbRA32, TbRA36 and the overlapping clones TbRA35 and TbRA12 (SEQ ID Nos.63, 77, 81, 82, 64, 67, 69, 71, 75, 78, 80, 79, 66). The clone TbRa24 isoverlapping with clone TbRa29.

The results of PBMC proliferation and interferon-γ assays performed onrepresentative recombinant antigens, and using T-cell preparations fromseveral different M. tuberculosis-immune patients, are presented inTables 2 and 3, respectively.

TABLE 2 RESULTS OF PBMC PROLIFERATION TO REPRESENTATIVE SOLUBLE ANTIGENSPatient Antigen 1 2 3 4 5 6 7 8 9 10 11 12 13 TbRa1 − − ± ++ − − ± ± −− + ± − TbRa3 − ± ++ − ± − − ++ ± − − − − TbRa9 − − nt nt ++ ++ nt nt ntnt nt nt nt TbRa10 − − ± ± ± + nt ± − + ± ± − TbRa11 ± ± + ++ ++ + nt −++ ++ ++ ± nt TbRa12 − − + + ± ++ + ± ± − + − − TbRa16 nt nt nt nt − +nt nt nt nt nt nt nt TbRa24 nt nt nt nt − − nt nt nt nt nt nt nt TbRa26− + nt nt − − nt nt nt nt nt nt nt TbRa29 nt nt nt nt − − nt nt nt nt ntnt nt TbRa35 ++ nt ++ ++ ++ ++ nt ++ ++ ++ ++ ++ nt TbRaB nt nt nt nt −− nt nt nt nt nt nt nt TbRaC nt nt nt nt − − nt nt nt nt nt nt nt TbRaDnt nt nt nt − − nt nt nt nt nt nt nt AAMK − − ± − − − nt − − − nt ± ntYY − − − − − − nt − − − nt + nt DPEP − + − ++ − − nt ++ ± + ± ± ntControl − − − − − − − − − − − − − nt = not tested

TABLE 3 RESULTS OF PBMC INTERFERON-γ PRODUCTION TO REPRESENTATIVESOLUBLE ANTIGENS Patient Antigen 1 2 3 4 5 6 7 8 9 10 11 12 13 TbRa1 +++ +++ + − ± − − + ± − TbRa3 − ± ++ − ± − − ++ ± − − − − TbRa9 ++ + ntnt ++ − nt nt nt nt nt nt nt TbRa10 + + ± ± ± + nt ± − + ± ± − TbRa11± + ++ ++ + nt − ++ ++ ++ ± nt TbRa12 − − + + ± +++ + ± ± − + − − TbRa16nt nt nt nt + + nt nt nt nt nt nt nt TbRa24 nt nt nt nt + − nt nt nt ntnt nt nt TbRa26 ++ ++ nt nt + + nt nt nt nt nt nt nt TbRa29 nt nt ntnt + − nt nt nt nt nt nt nt TbRa35 ++ nt ++ ++ +++ +++ nt ++ ++ +++ +++++ nt TbRaB nt nt nt nt ++ + nt nt nt nt nt nt nt TbRaC nt nt nt nt + +nt nt nt nt nt nt nt TbRaD nt nt nt nt + + nt nt nt nt nt nt nt AAMK − −± − − − nt − − − nt ± nt YY − − − − − − nt − − − nt + nt DPEP + + ++++ + − nt +++ ± + ± ± nt Control − − − − − − − − − − − − −

In Tables 2 and 3, responses that gave a stimulation index (SI) ofbetween 1.2 and 2 (compared to cells cultured in medium alone) werescored as ±, a SI of 2-4 was scored as +, as SI of 4-8 or 2-4 at aconcentration of 1 μg or less was scored as ++ and an SI of greater than8 was scored as +++. In addition, the effect of concentration onproliferation and interferon-γ production is shown for two of the aboveantigens in the attached Figure. For both proliferation and interferon-γproduction, TbRa3 was scored as ++ and TbRa9 as +.

These results indicate that these soluble antigens can induceproliferation and/or interferon-γ production in T-cells derived from anM. tuberculosis-immune individual.

B. Use of Sera from Patients Having Pulmonary of Pleural Tuberculosis toIdentify DNA Sequences Encoding M. Tuberculosis Antigens

The genomic DNA library described above, and an additional H37Rvlibrary, were screened using pools of sera obtained from patients withactive tuberculosis. To prepare the H37Rv library, M. tuberculosisstrain H37Rv genomic DNA was isolated, subjected to partial Sau3Adigestion and used to construct an expression library using the LambdaZap expression system (Stratagene, La Jolla, Calif.). Three differentpools of sera, each containing sera obtained from three individuals withactive pulmonary or pleural disease, were used in the expressionscreening. The pools were designated TbL, TbM and TbH, referring torelative reactivity with H37Ra lysate (i.e., TbL=low reactivity,TbM=medium reactivity and TbH=high reactivity) in both ELISA andimmunoblot format. A fourth pool of sera from seven patients with activepulmonary tuberculosis was also employed. All of the sera lackedincreased reactivity with the recombinant 38 kD M. tuberculosis H37Raphosphate-binding protein.

All pools were pre-adsorbed with E. coli lysate and used to screen theH37Ra and H37Rv expression libraries, as described in Sambrook et al.,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories,Cold Spring Harbor, N.Y., 1989. Bacteriophage plaques expressingimmunoreactive antigens were purified. Phagemid from the plaques wasrescued and the nucleotide sequences of the M. tuberculosis clonesdeduced.

Thirty two clones were purified. Of these, 31 represented sequences thathad not been previously identified in human M. tuberculosis.Representative sequences of the DNA molecules identified are provided inSEQ ID Nos.: 26-51 and 105. Of these, TbH-8-2 (SEQ. ID NO. 105) is apartial clone of TbH-8, and TbH-4 (SEQ. ID NO. 43) and TbH-4-FWD (SEQ.ID NO. 44) are non-contiguous sequences from the same clone. Amino acidsequences for the antigens hereinafter identified as Tb38-1, TbH-4,TbH-8, TbH-9, and TbH-12 are shown in SEQ ID Nos.: 88-92. Comparison ofthese sequences with known sequences in the gene bank using thedatabases identified above revealed no significant homologies to TbH-4,TbH-8, TbH-9 and TbM-3, although weak homologies were found to TbH-9.TbH-12 was found to be homologous to a 34 kD antigenic proteinpreviously identified in M. paratuberculosis (Acc. No. S28515). Tb38-1was found to be located 34 base pairs upstream of the open reading framefor the antigen ESAT-6 previously identified in M. bovis (Acc. No.U34848) and in M. tuberculosis (Sorensen et al., Infec. Immun.63:1710-1717, 1995).

Probes derived from Tb38-1 and TbH-9, both isolated from an H37Ralibrary, were used to identify clones in an H37Rv library. Tb38-1hybridized to Tb38-1F2, Tb38-1F3, Tb38-1F5 and Tb38-1F6 (SEQ. ID NOS.112, 113, 116, 118, and 119). (SEQ ID NOS. 112 and 113 arenon-contiguous sequences from clone Tb38-1F2.) Two open reading frameswere deduced in Tb38-IF2; one corresponds to Tb37FL (SEQ. ID. NO. 114),the second, a partial sequence, may be the homologue of Tb38-1 and iscalled Tb38-IN (SEQ. ID NO. 115). The deduced amino acid sequence ofTb38-1F3 is presented in SEQ. ID. NO. 117. A TbH-9 probe identifiedthree clones in the H37Rv library: TbH-9-FL (SEQ. ID NO. 106), which maybe the homologue of TbH-9 (R37Ra), TbH-9-1 (SEQ ID NO.108), and TbH-9-4(SEQ. ID NO 110), all of which are highly related sequences to TbH-9.The deduced amino acid sequences for these three clones are presented inSEQ ID NOS. 107, 109 and 111.

Further screening of the M. tuberculosis genomic DNA library, asdescribed above, resulted in the recovery of ten additional reactiveclones, representing seven different genes. One of these genes wasidentified as the 38 Kd antigen discussed above, one was determined tobe identical to the 14 Kd alpha crystallin heat shock protein previouslyshown to be present in M. tuberculosis, and a third was determined to beidentical to the antigen TbH-8 described above. The determined DNAsequences for the remaining five clones (hereinafter referred to asTbH-29, TbH-30, TbH-32 and TbH-33) are provided in SEQ ID NO: 138-141,respectively, with the corresponding predicted amino acid sequencesbeing provided in SEQ ID NO: 142-145, respectively. The DNA and aminoacid sequences for these antigens were compared with those in the genebank as described above. No homologies were found to the 5′ end ofTbH-29 (which contains the reactive open reading frame), although the 3′end of TbH-29 was found to be identical to the M. tuberculosis cosmidY227. TbH-32 and TbH-33 were found to be identical to the previouslyidentified M. tuberculosis insertion element IS6110 and to the M.tuberculosis cosmid Y50, respectively. No significant homologies toTbH-30 were found.

Positive phagemid from this additional screening were used to infect E.coli XL-1 Blue MRF′, as described in Sambrook et al., supra. Inductionof recombinant protein was accomplished by the addition of IPTG. Inducedand uninduced lysates were run in duplicate on SDS-PAGE and transferredto nitrocellulose filters. Filters were reacted with human M.tuberculosis sera (1:200 dilution) reactive with TbH and a rabbit sera(1:200 or 1:250 dilution) reactive with the N-terminal 4 Kd portion oflacZ. Sera incubations were performed for 2 hours at room temperature.Bound antibody was detected by addition of ¹²⁵I-labeled Protein A andsubsequent exposure to film for variable times ranging from 16 hours to11 days. The results of the immunoblots are summarized in Table 4.

TABLE 4 Human M. tb Anti-lacZ Antigen Sera Sera TbH-29 45 Kd 45 KdTbH-30 No reactivity 29 Kd TbH-32 12 Kd 12 Kd TbH-33 16 Kd 16 Kd

Positive reaction of the recombinant human M. tuberculosis antigens withboth the human M. tuberculosis sera and anti-lacZ sera indicate thatreactivity of the human M. tuberculosis sera is directed towards thefusion protein. Antigens reactive with the anti-lacZ sera but not withthe human M. tuberculosis sera may be the result of the human M.tuberculosis sera recognizing conformational epitopes, or theantigen-antibody binding kinetics may be such that the 2 hour seraexposure in the immunoblot is not sufficient.

The results of T-cell assays performed on Tb38-1, ESAT-6 and otherrepresentative recombinant antigens are presented in Tables 5A, B and 6,respectively, below:

TABLE 5A RESULTS OF PBMC PROLIFERATION TO REPRESENTATIVE ANTIGENS DonorAntigen 1 2 3 4 5 6 7 8 9 10 11 Tb38.1 +++ + − − − ++ − + − ++ +++ESAT-6 +++ + + + − + − + + ++ +++ TbH-9 ++ ++ − ++ ± ± ++ ++ ++ ++ ++

TABLE 5B RESULTS OF PBMC INTERFERON-γ PRODUCTION TO REPRESENTATIVEANTIGENS Donor Antigen 1 2 3 4 5 6 7 8 9 10 11 Tb38.1 +++ + − + + +++ −++ − +++ +++ ESAT-6 +++ + + + +− + − + + +++ +++ TbH-9 ++ ++ − +++ ± ±+++ +++ ++ +++ ++

TABLE 6 SUMMARY OF T-CELL RESPONSES TO REPRESENTATIVE ANTIGENSProliferation Interferon-γ Antigen patient 4 patient 5 patient 6 patient4 patient 5 patient 6 total TbH9 ++ ++ ++ +++ ++ ++ 13 TbM7 − + − ++ + −4 TbH5 − + + ++ ++ ++ 8 TbL23 − + ± ++ ++ + 7.5 TbH4 − ++ ± ++ ++ ± 7−control − − − − − − 0

These results indicate that both the inventive M. tuberculosis antigensand ESAT-6 can induce proliferation and/or interferon-γ production inT-cells derived from an M. tuberculosis-immune individual. To the bestof the inventors' knowledge, ESAT-6 has not been previously shown tostimulate human immune responses

A set of six overlapping peptides covering the amino acid sequence ofthe antigen Tb38-1 was constructed using the method described in Example6. The sequences of these peptides, hereinafter referred to as pep1-6,are provided in SEQ ID Nos. 93-98, respectively. The results of T-cellassays using these peptides are shown in Tables 7 and 8. These resultsconfirm the existence, and help to localize T-cell epitopes withinTb38-1 capable of inducing proliferation and interferon-γ production inT-cells derived from an M. tuberculosis immune individual.

TABLE 7 RESULTS OF PBMC PROLIFERATION TO TB38-1 PEPTIDES Patient Peptide1 2 3 4 5 6 7 8 9 10 11 12 13 pep1 − − − − ± − − − − ± − − + pep2 ± − −− ± − − − ± ± − − + pep3 − − − − − − − − ± − − − ± pep4 ++ − − − − − + −± ± − − + pep5 ++ ± − − − − + − ± − − − + pep6 − ++ − − − − ± − ± + −− + Control − − − − − − − − − − − − −

TABLE 8 RESULTS OF PBMC INTERFERON-γ PRODUCTION TO TB38-1 PEPTIDESPatient Peptide 1 2 3 4 5 6 7 8 9 10 11 12 13 pep1 + − − − ± − − − − ± −− + pep2 − − − ± − − − ± ± − − + pep3 − − − − − − − − ± − − − ± pep4 ++− − − − − + − ± ± − − + pep5 ++ ± − − − − + − ± − − − + pep6 + ++ − − −− ± − ± + − − + Control − − − − − − − − − − − − −

Studies were undertaken to determine whether the antigens TbH-9 andTb38-1 represent cellular proteins or are secreted into M. tuberculosisculture media. In the first study, rabbit sera were raised against A)secretory proteins of M. tuberculosis, B) the known secretoryrecombinant M. tuberculosis antigen 85b, C) recombinant Tb38-1 and D)recombinant TbH-9, using protocols substantially the same as that asdescribed in Example 3A. Total M. tuberculosis lysate, concentratedsupernatant of M. tuberculosis cultures and the recombinant antigens85b, TbH-9 and Tb38-1 were resolved on denaturing gels, immobilized onnitrocellulose membranes and duplicate blots were probed using therabbit sera described above.

The results of this analysis using control sera (panel I) and antisera(panel II) against secretory proteins, recombinant 85b, recombinantTb38-1 and recombinant TbH-9 are shown in FIGS. 3A-D, respectively,wherein the lane designations are as follows: 1) molecular weightprotein standards; 2) 5 μg of M. tuberculosis lysate; 3) 5 μg secretoryproteins; 4) 50 ng recombinant Tb38-1; 5) 50 ng recombinant TbH-9; and6) 50 ng recombinant 85b. The recombinant antigens were engineered withsix terminal histidine residues and would therefore be expected tomigrate with a mobility approximately 1 kD larger that the nativeprotein. In FIG. 3D, recombinant TbH-9 is lacking approximately 10 kD ofthe full-length 42 kD antigen, hence the significant difference in thesize of the immunoreactive native TbH-9 antigen in the lysate lane(indicated by an arrow). These results demonstrate that Tb38-1 and TbH-9are intracellular antigens and are not actively secreted by M.tuberculosis.

The finding that TbH-9 is an intracellular antigen was confirmed bydetermining the reactivity of TbH-9-specific human T cell clones torecombinant TbH-9, secretory M. tuberculosis proteins and PPD ATbH-9-specific T cell clone (designated 131TbH-9) was generated fromPBMC of a healthy PPD-positive donor. The proliferative response of131TbH-9 to secretory proteins, recombinant TbH-9 and a control M.tuberculosis antigen, TbRa11, was determined by measuring uptake oftritiated thymidine, as described in Example 1. As shown in FIG. 4A, theclone 131TbH-9 responds specifically to TbH-9, showing that TbH-9 is nota significant component of M. tuberculosis secretory proteins. FIG. 413shows the production of IFN-γ by a second TbH-9-specific T cell clone(designated PPD 800-10) prepared from PBMC from a healthy PPD-positivedonor, following stimulation of the T cell clone with secretoryproteins, PPD or recombinant TbH-9. These results further confirm thatTbH-9 is not secreted by M. tuberculosis.

C. Use of Sera from Patients Having Extrapulmonary Tuberculosis toIdentify DNA Sequences Encoding M. Tuberculosis Antigens

Genomic DNA was isolated from M. tuberculosis Erdman strain, randomlysheared and used to construct an expression library employing the LambdaZAP expression system (Stratagene, La Jolla, Calif.). The resultinglibrary was screened using pools of sera obtained from individuals withextrapulmonary tuberculosis, as described above in Example 3B, with thesecondary antibody being goat anti-human IgG+A+M (H+L) conjugated withalkaline phosphatase.

Eighteen clones were purified. Of these, 4 clones (hereinafter referredto as XP14, XP24, XP31 and XP32) were found to bear some similarity toknown sequences. The determined DNA sequences for XP14, XP24 and XP31are provided in SEQ ID Nos.: 156-158, respectively, with the 5′ and 3′DNA sequences for XP32 being provided in SEQ ID Nos.: 159 and 160,respectively. The predicted amino acid sequence for XP14 is provided inSEQ ID No: 161. The reverse complement of XP14 was found to encode theamino acid sequence provided in SEQ ID No.: 162.

Comparison of the sequences for the remaining 14 clones (hereinafterreferred to as XP1-XP6, XP17-XP19, XP22, XP25, XP27, XP30 and XP36) withthose in the genebank as described above, revealed no homologies withthe exception of the 3′ ends of XP2 and XP6 which were found to bearsome homology to known M. tuberculosis cosmids. The DNA sequences forXP27 and XP36 are shown in SEQ ID Nos.: 163 and 164, respectively, withthe 5′ sequences for XP4, XP5, XP17 and XP30 being shown in SEQ ID Nos:165-168, respectively, and the 5′ and 3′ sequences for XP2, XP3, XP6,XP18, XP19, XP22 and XP25 being shown in SEQ ID Nos: 169 and 170; 171and 172; 173 and 174; 175 and 176; 177 and 178; 179 and 180; and 181 and182, respectively. XP1 was found to overlap with the DNA sequences forTbH4, disclosed above. The full-length DNA sequence for TbH4-XP1 isprovided in SEQ ID No.: 183. This DNA sequence was found to contain anopen reading frame encoding the amino acid sequence shown in SEQ ID No:184. The reverse complement of TbH4-XP1 was found to contain an openreading frame encoding the amino acid sequence shown in SEQ ID No.: 185.The DNA sequence for XP36 was found to contain two open reading framesencoding the amino acid sequence shown in SEQ ID Nos.: 186 and 187, withthe reverse complement containing an open reading frame encoding theamino acid sequence shown in SEQ ID No.: 188.

Recombinant XP1 protein was prepared as described above in Example 3B,with a metal ion affinity chromatography column being employed forpurification. As illustrated in FIGS. 8A-B and 9A-B, using the assaysdescribed herein, recombinant XP1 was found to stimulate cellproliferation and IFN-γ production in T cells isolated from an M.tuberculosis-immune donors.

D. Use of a Lysate Positive Serum Pool from Patients Having Tuberculosisto Identify DNA Sequences Encoding M. Tuberculosis Antigens

Genomic DNA was isolated from M. tuberculosis Erdman strain, randomlysheared and used to construct an expression library employing the LambdaScreen expression system (Novagen, Madison, Wis.), as described below inExample 6. Pooled serum obtained from M. tuberculosis-infected patientsand that was shown to react with M. tuberculosis lysate but not with thepreviously expressed proteins 38 kD, Tb38-1, TbRa3, TbH4, DPEP andTbRa11, was used to screen the expression library as described above inExample 3B, with the secondary antibody being goat anti-human IgG+A+M(H+L) conjugated with alkaline phosphatase.

Twenty-seven clones were purified. Comparison of the determined cDNAsequences for these clones revealed no significant homologies to 10 ofthe clones (hereinafter referred to as LSER-10, LSER-11, LSER-12,LSER-13, LSER-16, LSER-18, LSER-23, LSER-24, LSER-25 and LSER-27). Thedetermined 5′ cDNA sequences for LSER-10, LSER-11, LSER-12, LSER-13,LSER-16 and LSER-25 are provided in SEQ ID NO: 242-247, respectively,with the corresponding predicted amino acid sequences for LSER-10,LSER-12, LSER-13, LSER-16 and LSER-25 being provided in SEQ ID NO:248-252, respectively. The determined full-length cDNA sequences forLSER-18, LSER-23, LSER-24 and LSER-27 are shown in SEQ ID NO: 253-256,respectively, with the corresponding predicted amino acid sequencesbeing provided in SEQ ID NO: 257-260. The remaining seventeen cloneswere found to show similarities to unknown sequences previouslyidentified in M. tuberculosis. The determined 5′ cDNA sequences forsixteen of these clones (hereinafter referred to as LSER-1, LSER-3,LSER-4, LSER-5, LSER-6, LSER-8, LSER-14, LSER-15, LSER-17, LSER-19,LSER-20, LSER-22, LSER-26, LSER-28, LSER-29 and LSER-30) are provided inSEQ ID NO: 261-276, respectively, with the corresponding predicted aminoacid sequences for LSER-1, LSER-3, LSER-5, LSER-6, LSER-8, LSER-14,LSER-15, LSER-17, LSER-19, LSER-20, LSER-22, LSER-26, LSER-28, LSER-29and LSER-30 being provided in SEQ ID NO: 277-291, respectively. Thedetermined full-length cDNA sequence for the clone LSER-9 is provided inSEQ ID NO: 292. The reverse complement of LSER-6 (SEQ ID NO: 293) wasfound to encode the predicted amino acid sequence of SEQ ID NO: 294.

E. Preparation of M. Tuberculosis Soluble Antigens Using RabbitAnti-Sera Raised Against M. Tuberculosis Fractionated Proteins

M. tuberculosis lysate was prepared as described above in Example 2. Theresulting material was fractionated by HPLC and the fractions screenedby Western blot for serological activity with a serum pool from M.tuberculosis-infected patients which showed little or noimmunoreactivity with other antigens of the present invention. Rabbitanti-sera was generated against the most reactive fraction using themethod described in Example 3A. The anti-sera was used to screen an M.tuberculosis Erdman strain genomic DNA expression library prepared asdescribed above. Bacteriophage plaques expressing immunoreactiveantigens were purified. Phagemid from the plaques was rescued and thenucleotide sequences of the M. tuberculosis clones determined.

Ten different clones were purified. Of these, one was found to beTbRa35, described above, and one was found to be the previouslyidentified M. tuberculosis antigen, HSP60. Of the remaining eightclones, seven (hereinafter referred to as RDIF2, RDIF5, RDIF8, RDIF10,RDIF11 and RDIF 12) were found to bear some similarity to previouslyidentified M. tuberculosis sequences. The determined DNA sequences forRDIF2, RDIF5, RDIF8, RDIF10 and RDIF11 are provided in SEQ ID Nos.:189-193, respectively, with the corresponding predicted amino acidsequences being provided in SEQ ID Nos: 194-198, respectively. The 5′and 3′ DNA sequences for RDIF12 are provided in SEQ ID Nos.: 199 and200, respectively. No significant homologies were found to the antigenRDIF-7. The determined DNA and predicted amino acid sequences for RDIF7are provided in SEQ ID Nos.: 201 and 202, respectively. One additionalclone, referred to as RDIF6 was isolated, however, this was found to beidentical to RDIF5.

Recombinant RDIF6, RDIF8, RDIF10 and RDIF11 were prepared as describedabove. As shown in FIGS. 8A-B and 9A-B, these antigens were found tostimulate cell proliferation and IFN-γ production in T cells isolatedfrom M. tuberculosis-immune donors.

Example 4 Purification and Characterization of a Polypeptide fromTuberculin Purified Protein Derivative

An M. tuberculosis polypeptide was isolated from tuberculin purifiedprotein derivative (PPD) as follows.

PPD was prepared as published with some modification (Seibert, F. etal., Tuberculin purified protein derivative. Preparation and analyses ofa large quantity for standard. The American Review of Tuberculosis44:9-25, 1941).

M. tuberculosis Rv strain was grown for 6 weeks in synthetic medium inroller bottles at 37° C. Bottles containing the bacterial growth werethen heated to 100° C. in water vapor for 3 hours. Cultures were sterilefiltered using a 0.22μ filter and the liquid phase was concentrated 20times using a 3 kD cut-off membrane. Proteins were precipitated oncewith 50% ammonium sulfate solution and eight times with 25% ammoniumsulfate solution. The resulting proteins (PPD) were fractionated byreverse phase liquid chromatography (RP-HPLC) using a C18 column(7.8×300 mM; Waters, Milford, Mass.) in a Biocad HPLC system (PerseptiveBiosystems, Framingham, Mass.). Fractions were eluted from the columnwith a linear gradient from 0-100% buffer (0.1% TFA in acetonitrile).The flow rate was 10 ml/minute and eluent was monitored at 214 nm and280 nm.

Six fractions were collected, dried, suspended in PBS and testedindividually in M. tuberculosis-infected guinea pigs for induction ofdelayed type hypersensitivity (DTH) reaction. One fraction was found toinduce a strong DTH reaction and was subsequently fractionated furtherby RP-HPLC on a microbore Vydac C18 column (Cat. No. 218TP5115) in aPerkin Elmer/Applied Biosystems Division Model 172 HPLC. Fractions wereeluted with a linear gradient from 5-100% buffer (0.05% TFA inacetonitrile) with a flow rate of 80 μl/minute. Eluent was monitored at215 nm. Eight fractions were collected and tested for induction of DTHin M. tuberculosis-infected guinea pigs. One fraction was found toinduce strong DTH of about 16 mm induration. The other fractions did notinduce detectable DTH. The positive fraction was submitted to SDS-PAGEgel electrophoresis and found to contain a single protein band ofapproximately 12 kD molecular weight.

This polypeptide, herein after referred to as DPPD, was sequenced fromthe amino terminal using a Perkin Elmer/Applied Biosystems DivisionProcise 492 protein sequencer as described above and found to have theN-terminal sequence shown in SEQ ID No.: 129. Comparison of thissequence with known sequences in the gene bank as described aboverevealed no known homologies. Four cyanogen bromide fragments of DPPDwere isolated and found to have the sequences shown in SEQ ID Nos.:130-133. A subsequent search of the M. tuberculosis genome databasereleased by the Institute for Genomic Research revealed a match of theDPPD partial amino acid sequence with a sequence present within the M.tuberculosis cosmid MTY21C12. An open reading frame of 336 bp wasidentified. The full-length DNA sequence for DPPD is provided in SEQ IDNO: 240, with the corresponding full-length amino acid sequence beingprovided in SEQ ID NO: 241.

The ability of the antigen DPPD to stimulate human PBMC to proliferateand to produce IFN-γ was assayed as described in Example 1. As shown inTable 9, DPPD was found to stimulate proliferation and elicit productionof large quantities of IFN-γ; more than that elicited by commercial PPD.

TABLE 9 RESULTS OF PROLIFERATION AND INTERFERON-γ ASSAYS TO DPPD IFN-γPBMC Donor Stimulator Proliferation (CPM) (OD₄₅₀) A Medium 1,089 0.17PPD (commercial) 8,394 1.29 DPPD 13,451 2.21 B Medium 450 0.09 PPD(commercial) 3,929 1.26 DPPD 6,184 1.49 C Medium 541 0.11 PPD(commercial) 8,907 0.76 DPPD 23,024 >2.70

Example 5 Use of Sera from Tuberculosis-Infected Monkeys to Identify DNASequences Encoding M. Tuberculosis Antigens

Genomic DNA was isolated from M. tuberculosis Erdman strain, randomlysheared and used to construct an expression library employing the LambdaZAP expression system (Stratagene, La Jolla, Calif.). Serum samples wereobtained from a cynomolgous monkey 18, 33, 51 and 56 days followinginfection with M. tuberculosis Erdman strain. These samples were pooledand used to screen the M. tuberculosis genomic DNA expression libraryusing the procedure described above in Example 3C.

Twenty clones were purified. The determined 5′ DNA sequences for theclones referred to as MO-1, MO-2, MO-4, MO-8, MO-9, MO-26, MO-28, MO-29,MO-30, MO-34 and MO-35 are provided in SEQ ID NO: 215-225, respectively,with the corresponding predicted amino acid sequences being provided inSEQ ID NO: 226-236. The full-length DNA sequence of the clone MO-10 isprovided in SEQ ID NO: 237, with the corresponding predicted amino acidsequence being provided in SEQ ID NO: 238. The 3′ DNA sequence for theclone MO-27 is provided in SEQ ID NO: 239.

Clones MO-1, MO-30 and MO-35 were found to show a high degree ofrelatedness and showed some homology to a previously identified unknownM. tuberculosis sequence and to cosmid MTCI237. MO-2 was found to showsome homology to aspartokinase from M. tuberculosis. Clones MO-3, MO-7and MO-27 were found to be identical and to show a high degree ofrelatedness to MO-5. All four of these clones showed some homology to M.tuberculosis heat shock protein 70. MO-27 was found to show somehomology to M. tuberculosis cosmid MTCY339. MO-4 and MO-34 were found toshow some homology to cosmid SCY21B4 and M. smegmatis integration hostfactor, and were both found to show some homology to a previouslyidentified, unknown M. tuberculosis sequence. MO-6 was found to showsome homology to M. tuberculosis heat shock protein 65. MO-8, MO-9,MO-10, MO-26 and MO-29 were found to be highly related to each other andto show some homology to M. tuberculosis dihydrolipamidesuccinyltransferase. MO-28, MO-31 and MO-32 were found to be identicaland to show some homology to a previously identified M. tuberculosisprotein. MO-33 was found to show some homology to a previouslyidentified 14 kDa M. tuberculosis heat shock protein.

Further studies using the above protocol resulted in the isolation of anadditional four clones, hereinafter referred to as MO-12, MO-13, MO-19and MO-39. The determined 5′ cDNA sequences for these clones areprovided in SEQ ID NO: 295-298, respectively, with the correspondingpredicted protein sequences being provided in SEQ ID NO: 299-302,respectively. Comparison of these sequences with those in the gene bankas described above revealed no significant homologies to MO-39. MO-12,MO-13 and MO-19 were found to show some homologies to unknown sequencespreviously isolated from M. tuberculosis.

Example 6 Isolation of DNA Sequences Encoding M. Tuberculosis Antigensby Screening of a Novel Expression Library

This example illustrates isolation of DNA sequences encoding M.tuberculosis antigens by screening of a novel expression library withsera from M. tuberculosis-infected patients that were shown to beunreactive with a panel of the recombinant M. tuberculosis antigensTbRa11, TbRa3, Tb38-1, TbH4, TbF and 38 kD.

Genomic DNA from M. tuberculosis Erdman strain was randomly sheared toan average size of 2 kb, and blunt ended with Klenow polymerase,followed by the addition of EcoRI adaptors. The insert was subsequentlyligated into the Screen phage vector (Novagen, Madison, Wis.) andpackaged in vitro using the PhageMaker extract (Novagen). The resultinglibrary was screened with sera from several M. tuberculosis donors thathad been shown to be negative on a panel of previously identified M.tuberculosis antigens as described above in Example 3B.

A total of 22 different clones were isolated. By comparison, screeningof the λ Zap library described above using the same sera did not resultin any positive hits. One of the clones was found to represent TbRa11,described above. The determined 5′ cDNA sequences for 19 of theremaining 21 clones (hereinafter referred to as Erdsn1, Erdsn2,Erdsn4-Erdsn10, Erdsn12-18, Erdsn21-Erdsn23 and Erdsn25) are provided inSEQ ID NO: 303-322, respectively, with the determined 3′ cDNA sequencesfor Erdsn1, Erdsn2, Erdsn4, Erdsn-5, Erdsn-7-Erdsn10, Erdsn12-18,Erdsn21-Erdsn23 and Erdsn25 being provided in SEQ ID NO: 323-341,respectively. The complete cDNA insert sequence for the clone Erdsn24 isprovided in SEQ ID NO: 342. Comparison of the determined cDNA sequenceswith those in the gene bank revealed no significant homologies to thesequences provided in SEQ ID NO: 309, 316, 318-320, 322, 324, 328, 329,333, 335, 337, 339 and 341. The sequences of SEQ ID NO: 303-308,310-315, 317, 321, 323, 325-327, 330-332, 334, 336, 338, 340 and 342were found to show some homology to unknown sequences previouslyidentified in M. tuberculosis.

Example 7 Isolation of Soluble M. Tuberculosis Antigens Using MassSpectrometry

This example illustrates the use of mass spectrometry to identifysoluble M. tuberculosis antigens.

In a first approach, M. tuberculosis culture filtrate was screened byWestern analysis using serum from a tuberculosis-infected individual.The reactive bands were excised from a silver stained gel and the aminoacid sequences determined by mass spectrometry. The determined aminoacid sequence for one of the isolated antigens is provided in SEQ ID NO:343. Comparison of this sequence with those in the gene bank revealedhomology to the 85b precursor antigen previously identified in M.tuberculosis.

In a second approach, the high molecular weight region of M.tuberculosis culture supernatant was studied. This area may containimmunodominant antigens which may be useful in the diagnosis of M.tuberculosis infection. Two known monoclonal antibodies, IT42 and IT57(available from the Center for Disease Control, Atlanta, Ga.), showreactivity by Western analysis to antigens in this vicinity, althoughthe identity of the antigens remains unknown. In addition, unknownhigh-molecular weight proteins have been described as containing asurrogate marker for M. tuberculosis infection in HIV-positiveindividuals (Jnl. Infect. Dis., 176:133-143, 1997). To determine theidentity of these antigens, two-dimensional gel electrophoresis andtwo-dimensional Western analysis were performed using the antibodiesIT57 and IT42. Five protein spots in the high molecular weight regionwere identified, individually excised, enzymatically digested andsubjected to mass spectrometric analysis.

The determined amino acid sequences for three of these spots (referredto as spots 1, 2 and 4) are provided in SEQ ID NO: 344, 345-346 and 347,respectively. Comparison of these sequences with those in the gene bankrevealed that spot 1 is the previously identified PcK-1, aphosphoenolpyruvate kinase. The two sequences isolated from spot 2 weredetermined to be from two DNAks, previously identified in M.tuberculosis as heat shock proteins. Spot 4 was determined to be thepreviously identified M. tuberculosis protein Kat G. To the best of theinventors' knowledge, neither PcK-1 nor the two DNAks have previouslybeen shown to have utility in the diagnosis of M. tuberculosisinfection.

Example 8 Use of Representative Antigens for Diagnosis of Tuberculosis

This example illustrates the effectiveness of several representativepolypeptides in skin tests for the diagnosis of M. tuberculosisinfection.

Individuals were injected intradermally with 100 μl of either PBS or PBSplus Tween 20™ containing either 0.1 μg of protein (for TbH-9 andTbRa35) or 10 μg of protein (for TbRa38-1). Induration was measuredbetween 5-7 days after injection, with a response of 5 mm or greaterbeing considered positive. Of the 20 individuals tested, 2 were PPDnegative and 18 were PPD positive. Of the PPD positive individuals, 3had active tuberculosis, 3 had been previously infected withtuberculosis and 9 were healthy In a second study, 13 PPD positiveindividuals were tested with 0.1 μg TbRa11 in either PBS or PBS plusTween 20™ as described above. The results of both studies are shown inTable 10.

TABLE 10 RESULTS OF DTH TESTING WITH REPRESENTATIVE ANTIGENS TbH-9Tb38-1 Pos/ Pos/ TbRa35 Cumulative TbRa11 Total Total Pos/TotalPos/Total Pos/Total PPD negative 0/2 0/2 0/2 0/2 PPD positive healthy5/9 4/9 4/9 6/9 1/4 prior TB 3/5 2/5 2/5 4/5 3/5 active 3/4 3/4 0/4 4/41/4 TOTAL 11/18  9/18  6/18 14/18  5/13

Example 9 Synthesis of Synthetic Polypeptides

Polypeptides may be synthesized on a Millipore 9050 peptide synthesizerusing FMOC chemistry with HPTU(O-Benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate)activation. A Gly-Cys-Gly sequence may be attached to the amino terminusof the peptide to provide a method of conjugation or labeling of thepeptide. Cleavage of the peptides from the solid support may be carriedout using the following cleavage mixture: trifluoroaceticacid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleavingfor 2 hours, the peptides may be precipitated in coldmethyl-t-butyl-ether. The peptide pellets may then be dissolved in watercontaining 0.1% trifluoroacetic acid (TFA) and lyophilized prior topurification by C18 reverse phase HPLC. A gradient of 0%-60%acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) may beused to elute the peptides. Following lyophilization of the purefractions, the peptides may be characterized using electrospray massspectrometry and by amino acid analysis.

Example 10 Preparation and Characterization of M. Tuberculosis FusionProteins

A fusion protein containing TbRa3, the 38 kD antigen and Tb38-1 wasprepared as follows.

Each of the DNA constructs TbRa3, 38 kD and Tb38-1 were modified by PCRin order to facilitate their fusion and the subsequent expression of thefusion protein TbRa3-38 kD-Tb38-1. TbRa3, 38 kD and Tb38-1 DNA was usedto perform PCR using the primers PDM-64 and PDM-65 (SEQ ID NO: 146 and147), PDM-57 and PDM-58 (SEQ ID NO: 148 and 149), and PDM-69 and PDM-60(SEQ ID NO: 150 and 151), respectively. In each case, the DNAamplification was performed using 10 μl 10× Pfu buffer, 2 μl 10 mMdNTPs, 2 μl each of the PCR primers at 10 μM concentration, 81.5 μlwater, 1.5 μl Pfu DNA polymerase (Stratagene, La Jolla, Calif.) and 1 μlDNA at either 70 ng/μl (for TbRa3) or 50 ng/μl (for 38 kD and Tb38-1).For TbRa3, denaturation at 94° C. was performed for 2 min, followed by40 cycles of 96° C. for 15 sec and 72° C. for 1 min, and lastly by 72°C. for 4 min. For 38 kD, denaturation at 96° C. was performed for 2 min,followed by 40 cycles of 96° C. for 30 sec, 68° C. for 15 sec and 72° C.for 3 min, and finally by 72° C. for 4 min. For Tb38-1 denaturation at94° C. for 2 min was followed by 10 cycles of 96° C. for 15 sec, 68° C.for 15 sec and 72° C. for 1.5 min, 30 cycles of 96° C. for 15 sec, 64°C. for 15 sec and 72° C. for 1.5, and finally by 72° C. for 4 min.

The TbRa3 PCR fragment was digested with NdeI and EcoRI and cloneddirectly into pT7̂L2 IL 1 vector using NdeI and EcoRI sites. The 38 kDPCR fragment was digested with Sse8387I, treated with T4 DNA polymeraseto make blunt ends and then digested with EcoRI for direct cloning intothe pT7̂L2Ra3-1 vector which was digested with StuI and EcoRI. The 38-1PCR fragment was digested with Eco47III and EcoRI and directly subclonedinto pT7̂L2Ra3/38 kD-17 digested with the same enzymes. The whole fusionwas then transferred to pET28b—using NdeI and EcoRI sites. The fusionconstruct was confirmed by DNA sequencing.

The expression construct was transformed into BLR pLys S E. coli(Novagen, Madison, Wis.) and grown overnight in LB broth with kanamycin(30 μg/ml) and chloramphenicol (34 μg/ml). This culture (12 ml) was usedto inoculate 500 ml 2XYT with the same antibiotics and the culture wasinduced with IPTG at an OD560 of 0.44 to a final concentration of 1.2mM. Four hours post-induction, the bacteria were harvested and sonicatedin 20 mM Tris (8.0), 100 mM NaCl, 0.1% DOC, 20 μg/ml Leupeptin, 20 mMPMSF followed by centrifugation at 26,000×g. The resulting pellet wasresuspended in 8 M urea, 20 mM Tris (8.0), 100 mM NaCl and bound toPro-bond nickel resin (Invitrogen, Carlsbad, Calif.). The column waswashed several times with the above buffer then eluted with an imidazolegradient (50 mM, 100 mM, 500 mM imidazole was added to 8 M urea, 20 mMTris (8.0), 100 mM NaCl). The eluates containing the protein of interestwere then dialyzed against 10 mM Tris (8.0).

The DNA and amino acid sequences for the resulting fusion protein(hereinafter referred to as TbRa3-38 kD-Tb38-1) are provided in SEQ IDNO: 152 and 153, respectively.

A fusion protein containing the two antigens TbH-9 and Tb38-1(hereinafter referred to as TbH9-Tb38-1) without a hinge sequence, wasprepared using a similar procedure to that described above. The DNAsequence for the TbH9-Tb38-1 fusion protein is provided in SEQ ID NO:156.

The ability of the fusion protein TbH9-Tb38-1 to induce T cellproliferation and IFN-γ production in PBMC preparations was examinedusing the protocol described above in Example 1. PBMC from three donorswere employed: one who had been previously shown to respond to TbH9 butnot Tb38-1 (donor 131); one who had been shown to respond to Tb38-1 butnot TbH9 (donor 184); and one who had been shown to respond to bothantigens (donor 201). The results of these studies (FIGS. 5-7,respectively) demonstrate the functional activity of both the antigensin the fusion protein.

A fusion protein containing TbRa3, the antigen 38 kD, Tb38-1 and DPEPwas prepared as follows.

Each of the DNA constructs TbRa3, 38 kD and Tb38-1 were modified by PCRand cloned into vectors essentially as described above, with the primersPDM-69 (SEQ ID NO:150 and PDM-83 (SEQ ID NO: 205) being used foramplification of the Tb38-1A fragment. Tb38-1A differs from Tb38-1 by aDraI site at the 3′ end of the coding region that keeps the final aminoacid intact while creating a blunt restriction site that is in frame.The TbRa/38 kD/Tb38-1A fusion was then transferred to pET28b using NdeIand EcoRI sites.

DPEP DNA was used to perform PCR using the primers PDM-84 and PDM-85(SEQ ID NO: 206 and 207, respectively) and 1 μl DNA at 50 ng/μl.Denaturation at 94° C. was performed for 2 min, followed by 10 cycles of96° C. for 15 sec, 68° C. for 15 sec and 72° C. for 1.5 min; 30 cyclesof 96° C. for 15 sec, 64° C. for 15 sec and 72° C. for 1.5 min; andfinally by 72° C. for 4 min The DPEP PCR fragment was digested withEcoRI and Eco721 and clones directly into the pET28Ra3/38 kD/38-1Aconstruct which was digested with DraI and EcoRI. The fusion constructwas confirmed to be correct by DNA sequencing. Recombinant protein wasprepared as described above. The DNA and amino acid sequences for theresulting fusion protein (hereinafter referred to as TbF-2) are providedin SEQ ID NO: 208 and 209, respectively.

The reactivity of the fusion protein TbF-2 with sera from M.tuberculosis-infected patients was examined by ELISA using the protocoldescribed above. The results of these studies (Table 11) demonstratethat all four antigens function independently in the fusion protein.

TABLE 11 REACTIVITY OF TBF-2 FUSION RECOMBINANT WITH TB AND NORMAL SERATbF TbF-2 ELISA Reactivity Serum ID Status OD450 Status OD450 Status 38kD TbRa3 Tb38-1 DPEP B931-40 TB 0.57 + 0.321 + − + − + B931-41 TB0.601 + 0.396 + + + + − B931-109 TB 0.494 + 0.404 + + + ± − B931-132 TB1.502 + 1.292 + + + + ±  5004 TB 1.806 + 1.666 + ± ± + −  15004 TB2.862 + 2.468 + + + + −  39004 TB 2.443 + 1.722 + + + + −  68004 TB2.871 + 2.575 + + + + −  99004 TB 0.691 + 0.971 + − ± + − 107004 TB0.875 + 0.732 + − ± + −  92004 TB 1.632 + 1.394 + + ± ± −  97004 TB1.491 + 1.979 + + ± − + 118004 TB 3.182 + 3.045 + + ± − − 173004 TB3.644 + 3.578 + + + + − 175004 TB 3.332 + 2.916 + + + − − 274004 TB3.696 + 3.716 + − + − + 276004 TB 3.243 + 2.56 + − − + − 282004 TB1.249 + 1.234 + + − − − 289004 TB 1.373 + 1.17 + − + − − 308004 TB3.708 + 3.355 + − − + − 314004 TB 1.663 + 1.399 + − − + − 317004 TB1.163 + 0.92 + + − − − 312004 TB 1.709 + 1.453 + − + − − 380004 TB 0.238− 0.461 + − ± − + 451004 TB 0.18 − 0.2 − − − − ± 478004 TB 0.188 −0.469 + − − − ± 410004 TB 0.384 + 2.392 + ± − − + 411004 TB 0.306 +0.874 + − + − + 421004 TB 0.357 + 1.456 + − + − + 528004 TB 0.047 −0.196 − − − − + A6-87 Normal 0.094 − 0.063 − − − − − A6-88 Normal 0.214− 0.19 − − − − − A6-89 Normal 0.248 − 0.125 − − − − − A6-90 Normal 0.179− 0.206 − − − − − A6-91 Normal 0.135 − 0.151 − − − − − A6-92 Normal0.064 − 0.097 − − − − − A6-93 Normal 0.072 − 0.098 − − − − − A6-94Normal 0.072 − 0.064 − − − − − A6-95 Normal 0.125 − 0.159 − − − − −A6-96 Normal 0.121 − 0.12 − − − − − Cut-off 0.284 0.266 −

A fusion protein containing TbRa3, the antigen 38 kD, Tb38-1 and TbH4was prepared as follows.

Genomic M. tuberculosis DNA was used to PCR full-length TbH4 (FL TbH4)with the primers PDM-157 and PDM-160 (SEQ ID NO: 348 and 349,respectively) and 2 μl DNA at 100 ng/μl. Denaturation at 96° C. wasperformed for 2 min, followed by 40 cycles of 96° C. for 30 sec, 61° C.for 20 sec and 72° C. for 5 min; and finally by annealing at 72° C. for10 min. The FL TbH4 PCR fragment was digested with EcoRI and Sca I (NewEngland Biolabs.) and cloned directly into the pET28Ra3/38 kD38-1Aconstruct described above which was digested with DraI and EcoRI. Thefusion construct was confirmed to be correct by DNA sequencing.Recombinant protein was prepared as described above. The DNA and aminoacid sequences for the resulting fusion protein (hereinafter referred toas TbF-6) are provided in SEQ ID NO: 350 and 351, respectively.

A fusion protein containing the antigen 38 kD and DPEP separated by alinker was prepared as follows.

38 kD DNA was used to perform PCR using the primers PDM-176 and PDM-175(SEQ ID NO: 352 and 353, respectively), and 1 μl PET28Ra3/38kD/38-1/Ra2A-12 DNA at 110 ng/μl. Denaturation at 96° C. was performedfor 2 min, followed by 40 cycles of 96° C. for 30 sec, 71° C. for 15 secand 72° C. for 5 min and 40 sec; and finally by annealing at 72° C. for4 min. The two sets of primers PDM-171, PDM-172, and PDM-173, PDM-174were annealed by heating to 95° C. for 2 min and then ramping down to25° C. slowly at 0.1° C./sec. DPEP DNA was used to perform PCR asdescribed above The 38 kD fragment was digested with Eco RI (New EnglandBiolabs) and cloned into a modified pT7ΔL2 vector which was cut with Eco72 I (Promega) and Eco RI. The modified pT7ΔL2 construct was designed tohave a MGHHHHHH amino acid coding region in frame just 5′ of the Eco 72I site. The construct was digested with Kpn 2I (Gibco, BRL) and Pst I(New England Biolabs) and the annealed sets of phosphorylated primers(PDM-171, PDM-172 and PDM-173, PDM-174) were cloned in. The DPEP PCRfragment was digested with Eco RI and Eco 72 I and cloned into thissecond construct which was digested with Eco 47 III (New EnglandBiolabs) and Eco RI. Ligations were done with a ligation kit fromPanvera (Madison, Wis.). The resulting construct was digested with NdeI(New England Biolabs) and Eco RI, and transferred to a modified pET28vector. The fusion construct was confirmed to be correct by DNAsequencing.

Recombinant protein was prepared essentially as described above. The DNAand amino acid sequences for the resulting fusion protein (hereinafterreferred to as TbF-8) are provided in SEQ ID NO: 354 and 355,respectively.

One of skill in the art will appreciate that the order of the individualantigens within the fusion protein may be changed and that comparableactivity would be expected provided each of the epitopes is stillfunctionally available. In addition, truncated forms of the proteinscontaining active epitopes may be used in the construction of fusionproteins.

From the foregoing, it will be appreciated that, although specificembodiments of the invention have been described herein for the purposeof illustration, various modifications may be made without deviatingfrom the spirit and scope of the invention.

1-37. (canceled)
 38. An isolated polypeptide comprising: (i) an aminoacid sequence having at least 95% identity to the sequence of residues15 to 97 of SEQ ID NO:102; or (ii) an immunogenic fragment of thesequence of residues 15 to 97 of SEQ ID NO:102.
 39. The polypeptide ofclaim 38, comprising an amino acid sequence having at least 95% identityto the sequence of residues 15 to 97 of SEQ ID NO:102.
 40. Thepolypeptide of claim 38, comprising an immunogenic fragment of thesequence of residues 15 to 97 of SEQ ID NO:102.
 41. The polypeptide ofclaim 38, comprising the sequence of residues 15 to 97 of SEQ ID NO:102.42. The polypeptide of claim 38, consisting of: (i) an amino acidsequence having at least 95% identity to the sequence of residues 15 to97 of SEQ ID NO:102; or (ii) an immunogenic fragment of the sequence ofresidues 15 to 97 of SEQ ID NO:102.
 43. The polypeptide of claim 42,consisting of an amino acid sequence having at least 95% identity to thesequence of residues 15 to 97 of SEQ ID NO:102.
 44. The polypeptide ofclaim 42, consisting of an immunogenic fragment of the sequence ofresidues 15 to 97 of SEQ ID NO:102.
 45. The polypeptide of claim 42,consisting of the sequence of residues 15 to 97 of SEQ ID NO:102. 46.The polypeptide of claim 38, which is in a fusion protein.
 47. Thepolypeptide of claim 46, comprising the sequence of residues 15 to 97 ofSEQ ID NO:102.
 48. A composition comprising the polypeptide of claim 38and a pharmaceutically acceptable carrier.
 49. The composition of claim48, further comprising a non-specific immune response enhancer.
 50. Thecomposition of claim 49, wherein the non-specific immune responseenhancer is an adjuvant.
 51. The composition of claim 48, wherein thepolypeptide is in a fusion protein.
 52. The composition of claim 51,further comprising a non-specific immune response enhancer.
 53. Thecomposition of claim 52, wherein the non-specific immune responseenhancer is an adjuvant.
 54. A method for the treatment and/orprevention of tuberculosis comprising administering an effective amountof the polypeptide of claim
 38. 55. The method of claim 54, wherein thepolypeptide is in a fusion protein.